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ABSTRACT 
In the early 1970's, the Food and Drug Administration (FDA) launched an Over-
the-Counter (OTC) Drug Review with the objective of creating a uniform market 
containing medicines that are scientifically proven to be safe and effective for use without 
supervision of a physician. This project laid the groundwork for the switch policies and 
generated a tremendous amount of interest for improving or enhancing the concept of 
patient self-medication and providing a cost-effective alternative routine medical problems. 
One concern that has been expressed is that as more powerful prescription 
products enter the OTC market, the associated benefits of the drug may decrease while the 
risks increase as a result of less intervention by medical professionals. One solution to 
alleviate this concern may include better labeling and advertising for OTC products. It is 
established that these educational tools are relied upon by consumers. 
In this study, a survey was used to obtain information relative to consumer 
perceptions about usefulness of OTC medicines and the ease of reading and understanding 
product labels. It was found that 97 percent of consumers use OTCs to some extent. 
Most consumers responded that they read labels (92%), however, only 32 percent felt that 
OTC package labels were easy to read. Although more consumers (92%) felt that the 
labels were understandable, only half of the respondents could accurately define some of 
the terminology used in current package labeling. 
A second survey was used for physicians and pharmacists to elicit information 
about their views of consumer capability and readiness to use switch medicines (Rx-to-
OTC) in self-care. Only 50 percent of physicians and 74 percent of pharmacists approved 
of the trend of self-medication and even less (26% and 31 % ) from each group approved of 
switching prescription drugs to OTC status. Both groups of professionals, (88% of each) 
said they recommend OTC products, including switches, to their patients. 
This study showed that both consumers and health care professionals have 
confidence in OTC products, including those recently switched from prescription _status. It 
also revealed potential problems in the labeling and advertising of OTCs with respect to 
the general content of information. 
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PREFACE 
This dissertation is prepared in accordance with the University of Rhode Island 
" MANUSCRIPT THESIS PLAN'' option. The thesis is a collection of four manuscripts 
that address the issues of patient self-medication with over-the-counter (OTC) medicines. 
These issues have developed from the concern that as more prescription drugs achieve 
OTC status, patients are not being provided clear and sufficient information to use them 
properly. Manuscript I reviews the federal drug legislations and introduces the process of 
switching prescription medicines to OTC medicines. It has been submitted for review for 
publication to the Journal of Legal Medicine. Manuscript II elaborates on the Rx-to-
OTC switch trend and includes the perspectives of the regulating agencies, the drug 
manufacturers, and health care professionals regarding the changes in patient self-
medication and the availability of more medicines to improve this practice. This article has 
also been submitted for review for publication to the Journal of Legal Medicine . 
Manuscript III discusses the impact oflabeling and advertising on the promotion of safe 
and proper use of OTC medicines with emphasis on the switch products. Regulatory 
guidelines and developments for both educative tools are reviewed. This article has been 
accepted for publication in the Clinical Research and Regulatory Affairs journal. 
Manuscript IV presents a study consisting of three surveys designed to assess current 
consumer, pharmacist, and physician practices and perceptions of OTC medicines. This 
article has been submitted to the Drug Intelligence and Clinical Pharmacy journal. 
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MANUSCRIPT I 
A REGULATORY OVERVJEW OF THE CHANGING STANDARDS OF 
OVER-THE-COUNTER MEDICINES AVAILABLE TO 
CONSUMERS FOR SELF-MEDICATION 
A Regulatory Overview of the Changing Standards of Medicines 
( 
Available to Consumers for Self-Medication 
I. Introduction 
From passages in the Bible to the chapters in Remington's Pharmaceutical 
Sciences-the mention of drugs, their formulae for preparation, and their descriptions for 
use, give credence to the practice of self-medication as both an ancient human tradition 
and a modern science. 
Modern pharmacy as we know it evolved primarily during the 19th and 20th 
centuries. During that period, many new drugs were introduced increasing the number 
of preparations already in use or replacing those phasing out. Also occurring in the 19th 
century was the movement toward standardization of drug formulations through 
publication in compendia known as pharmacopoeias. The first edition of the United 
States Pharmacopoeia (USP) was written by doctors in 1820.(25) It contained a list of 
pharmaceutical preparations with their composition and technique for manufacturing. In 
-
1888, the first issue of National Formulary (NF), written by pharmacists, was published 
as a supplement to the USP containing drugs not included in the USP.(25) A third 
compendia, the Homeopathic Pharmacopoeia of the United States, was developed 
around the 1930s to include standards for homeopathic agents. 
The compendia formulary drugs were contrasted with coexisting numerous 
patent or proprietary medicines. Patented medicines were those in which ingredients and 
2 
I 
methods of formulating remained secret to all but who assigned them trademark names 
and sold them as such.(6) When the system of issuing patents to specific combinations of 
drugs was launched, it gave rise to the practice of establishing proprietary claims which 
were then universally accepted and protected under patent laws.(6,24) By the early 
1900's, the retail drug market became flooded with proprietary and patent medicines, all 
of which were accessible to consumers without the intervention of medical 
personnel.(6,24) 
The attitudes of the public toward the acceptance of medicines and their purpose 
for use have changed over time. At one time drugs were used primarily to treat sudden 
and transient illnesses or ailments. While this practice remains essentially unchanged, 
additional developments included the employment of drugs for their benefits in the 
treatment of serious or chronic conditions and the use of drugs in preventative medicine. 
The chronic administration of drugs in some cases extends the life of individuals who 
suffer from serious conditions like hypertension or diseases such as diabetes. In other 
cases, the routine use of vitamins, antianxiety agents, or sleep agents nurtures good 
physical or emotional health. 
As these conventional modes of drug use were employed by the public, 
confidence in their results grew and drugs became important resources in our society. 
The increasing role of drugs is exemplified by the amount of legislation designed and 
published in numerous volumes for the purpose of systemizing and regulating them. To 
encourage and support this status, pharmaceutical manufacturers grew in size and wealth 
in order to yield mass production and distribution of drugs.(6,24) 
3 
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In the beginning of the 1900s, there were three methods for consumers to obtain 
proprietary or patent drugs. (6,24) The traditional method was to visit a doctor, receive 
a prescription for a specific drug or combination of drugs, and take it to a pharmacist to 
fill . This seems to replicate the procedure observed toda;, however, the difference lies in 
the function of the prescription. In the early 1900s, all drugs or combinations of them 
were available to consumers with or without a doctor's order. If a pharmacist filled a 
prescription once, it then could be used as many different times and for as many different 
people as the pharmacist desired. In fact, if the drug or combination of drugs seemed to 
cure, mitigate or promise either result, the pharmacist could manufacture the product on 
a large scale, advertise it for the desired claims or ~ses, and sell it with no legal 
restrictions. ( 6, 10) Only about 25 percent of drug sales from drugstores were ordered 
by physician prescriptions.(24) 
4 
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Figure 1 
Copy of prescriptions from 1901, from New England area . 
. ~oacr:l'HE BOSTON ... CITY HOSPITAL. 
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Figure 2 
Copy of Pharmacist prescription log, 1907, from Rhode Island. 
6 
The second method for consumers to purchase drugs was to patronize the local 
drugstore and buy whatever they wished directly from the pharmacist. Approximately 
70 percent of drug sales arose from this practice. (6,24) It was during this time that the 
government attempted to prevent nonphysicians from practicing medicine through the 
enforcement of medical licensing laws.(2,6, 10,24) These laws ultimately restricted 
pharmacists from recommending a drug which they did not stock, since recommending 
would then be considered prescribing and only physicians retained the authority to 
prescribe. Their flexibility in selling or advertising any of their own commodities was not 
limited.(2,6) This initiative was important because 'it revealed the government's 
recognition for some form of regulation on drug~, however the law was weak in its 
capacity for controlling accessibility of potentially harmful or useless drugs. 
The third way for consumers to obtain drugs was to purchase them directly from 
doctors. Since doctors realized selling drugs was a way to increase business and enhance 
their incomes, they too participated in dispensing drugs. This method only accounted for 
about 5 percent of drug sales around 1929. (24) 
For those consumers who relied upon herbs as remedies, individual herbs or 
herbal preparations could be obtained from herbalists or homeopathic nonphysicians who 
formulated these products. 
7 
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Table 1 
Consumer expenditures for all medicines in selected years( dollars in millions). 
Year ($)Rx drugs ($)Drugs and drug sundries % Rx drugs 
1929 $190 $600 
1949 $940 $1640 
1969 $5395 $6480 
Sources: Rorem, C.R andFischelis, RP. The CostsofMedicines, pub. no. 14 ofthe 
Committee on the Cost of Medical Care. Chicago Univ. Press. Chicago (1932) 
Worthington, N. "National Health Care Expenditures, 1929-1974." Social Security 
Bulletin,38(Feb. 1975). 
*Rx stands for prescription (drugs). 
*This table reflects the percentage of prescription expenditures compared to the total 
amount of dollars spent on all drugs and health and beauty aids. 
8 
32% 
57% 
83% 
( Presently, there are two classes of drugs in the United States:nonprescription 
(OTC) and prescription drugs. Consumers have available to them a broad selection of 
over-the-counter medicines or they may call or visit their physician and obtain a written 
prescription for those medicines marketed under prescription-only status. 
If we look back through the history of the regulation of drugs, we can observe a 
cycle. At one time, all medicines were accessible to consumers without medical 
supervision but slowly, with developing laws, more and more medicines were shifted to 
prescription-only status. Presently, the prescription market is undergoing a major shift in 
the direction of the OTC market. Throughout the duration of this cycle, the goal of 
providing consumers with safe and effective medicines and the information to accompany 
them has always remained intact. 
IL History of the Food and Drug Administration 
The FDA originated in the Division of Chemistry within the U.S. Department of 
Agriculture.(2,8) Since the conditions in the drug and f?od industry were discovered to 
be unrefined and unsanitary, it became essential for the government to intervene and set 
guidelines for the production of safe food and drug products.(11) Therefore, in 1879, 
the Division of Chemistry undertook a major but important task of inspecting food and 
drug products for their safety, and manufacturing facilities for their cleanliness.(2,8) 
Congress expanded the divisions responsibilities and recognized it officially as 
the Bureau of Chemistry in 1883.(8) From that point on, the Bureau of Chemistry 
devoted its time to auditing and controlling food and drug provisions in the United 
9 
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States. To carry out its responsibilities, the Bureau implemented federal legislation 
aimed at protecting the public. A separate agency within the Bureau called the Food, 
Drug, & Insecticide Administration, and later renamed as the Food & Drug 
Administration in 1931, was organized for the purpose of enforcing these regulations. 
Until 1940, the FDA remained a part of the Department of Agriculture. At that time it 
was relocated to the Public Health Service which fell under the Federal Security Agency. 
Eventually, this agency became known as the Department of Health and Human 
Services.(2,8) 
The FDA, received its authority from Congr.ess, .acquired an increase in its realm 
of responsibilities, and activities through legislation. The mission of the FDA continues 
to revolve around protecting consumers from unsafe products and providing more 
truthful product information for them.(2,5) From its history, we can see how the FDA 
evolved from an inspection agency with limited police powers to a scientific, regulatory 
agency comprised of expert talent and knowledge, all of which are applied to assuring 
public safety from food and drug products. Today, challenges from the food and drug 
industry are presented to the FDA on a daily basis as a result of the developing 
technology in science and the improved education of consumers. 
m. Legislative overview 
A. Pure Food and Drug Law of 1906 
Food adulteration and contamination had been recognized as a problem for some 
time before this law was passed in 1906.(11) It was apparent that the integrity and 
10 
ethical standards of manufacturers were blunted by the struggle to sufVlve in an 
( 
increasingly competitive arena of business. The standards of safety that existed for the 
public were diminished to an all time low. Uptown :Sinclair, author of The Jungle, 
graphically disclosed the repulsive and unsanitary practices of meat packers and other 
producers of foodstuff. (1 l,24)The public response to this book pressured Congress to 
enact legislation which would set standards for these manufacturers to meet if they were 
to produce any food or drug for public consumption. The Pure Food and Drugs Act, 
which was signed into law in June 1906, addressed this issue.(20) 
The Pure Food and Drug Act specifically prohibited adulterated or misbranded 
food or drugs in interstate commerce.(20) The drugs covered under this law included all 
those (patent and formulary) accessible for consumer use. A drug was deemed to be 
"adulterated" if it deviated from the standards of p~rity or strength stated by the 
compendia without revealing as much on the package container. A drug was considered 
"misbranded" if it was sold under a false name or it failed to identify the list of 
ingredients and the quantities of addicting substances that the product contained.(20) 
There were obvious inadequacies with this law. First, it did not require 
manufacturers to disclose ingredients (outside of narcotics) in their preparations.(7,9) 
However, if the manufactures chose to do this, the FDA would monitor the accuracy of 
the disclosure. Also, those products containing several ingredients had to be reproduced 
consistently and under the same name. Last, any information provided on the container 
could not be false or misleading.(7,8,24) To bypass the requirements of this law, a 
. 
manufacturer could simply produce a nonnarcotic formula, call it an original name, and 
11 
provide very little information about it. The control of what products were to be made 
and sold was not affected by this law and therefore remained in the hands of 
manufacturers who continued to respond to consumer demand.(7) 
The pharmaceutical industry's sales increased sixfold from the time of the Pure 
Food and Drug Act to the beginning of the Depression. (24) Preparations manufactured 
by pharmacists and doctors accounted for 40 percent of the total medicines consumed by 
the public throughout this period. The remainder was comprised of patent or proprietary 
medicines which accounted for more than half of all drug sales in 1929. (24) 
B. The Harrison Narcotic Act of 1914 
At this point in time, this act was the first and only legislation which restricted 
sales of drugs and specified that any drug product containing opium or coca leaf 
derivatives could be sold only upon the receipt of a physician's written order. (7,15) 
Overall, this law had little impact over the vast number of drugs available to consumers. 
C. The Federal Food, Drug, and Cosmetic Act of 1938 (FD & C Act) 
In 1937, Massengill, a respected drug company, decided to market a drug that 
seemed to have miraculous antiinfective properties. This drug, known as sulfanilamide, 
had been used in powder form on topical wounds to prevent infection. Sulfanilamide 
was already marketed in tablet and capsule form for some time. The idea to sell this 
drug in liquid form was quickly implemented when the company found a compatible, 
pleasant- tasting vehicle, diethylene glycol. Without being tested for toxicity, this 
12 
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solution was produced, labeled Elixir Sulfanilamide, and marketed by September 
1937.(13) 
Subsequently, diethylene glycol was found to be toxic and the product caused 
approximately 100 deaths. Even though Massengill, which produced the elixir, was 
responsible for these deaths, the company could be prosecuted only for mislabeling under 
the 1906 Pure Food and Drug Act. It used the term "elixir" which implies an alcohol 
solution and this term was not appropriate for the product.(13,24) 
Consistent with prevailing conditions of the Pure Food and Drug Act of 1906, 
the occurrence of a health hazard aroused a pubiic outrage and resulted in a quick 
response from the legislators. It led to an amendment to this 1906 act renamed as the 
Federal Food, Drug, & Cosmetic Act of 1938. Additionally, the increasing sales and 
advertisements of medicines through the first quarter of this century presented a safety 
concern to the FDA This new amendment required that drugs and cosmetics be tested 
for safety with regard to intent of use and that they undergo an approval process. (15,22) 
For this discussion only drugs will be referenced. Since any drug can be considered 
harmful if used improperly, the manufacturers had to demonstrate the safety of the drug 
when used according to the conditions described in the labeling. The term "labeling" 
refers to the written or graphic material which is p_lace9 on the container or any of its 
wrappers which accompany the drug product. (26,27) According to the 1938 law, label 
information was to include the contents of the product and adequate directions for use in 
language understandable by persons of ordinary intelligence. (29) A further requirement 
of labeling was an inclusive warning which identified the drug product as one containing 
13 
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a narcotic or hypnotic ingredient.(29,31,33) This warning came to be known as the 
"Caution" warning and it stated: "Warning: May be habit forming."(26,31,35) 
The 1938 law also imposed restrictions on the variety of drugs which could be 
marketed, and it mandated that information about these drugs be provided to the 
consumer. The law as written, however, still seemed to allow the consumer to choose 
from the available drugs on the market. The FDA supported the concept of self-
medication through this legislation and, in fact, the goal was to improve or facilitate 
patient self-medication, not hinder it. The ultimate expectation of the 193 8 act was to 
make self-medication safe, but this goal appeared to be nullified by subsequent actions of 
the FDA. 
Among the regulations promulgating the enforcement of the FD & C Act was 
one which addressed labeling exemption. Those drug's in which safety could not be 
assured by adequate directions in the labeling would be exempted from the labeling 
requirement provided they were labeled with a cautionary statement.(28,31,35) This 
statement read "Caution: To be used only by or on the order of a physician." (28,31,35) 
This statement came to be known as the "Caution legend" and it was later revised to 
read "Caution: Federal Law prohibits dispensing without a prescription." (15) It was to 
be placed on packages of these medicines, thus identifying them to pharmacists and 
physicians as those which required a prescription. This legend was placed voluntarily on 
packages by manufacturers and the FDA approved them for marketing under this 
restricted status.(7,24) The decision as to which. me9icines should bear the caution 
legend was primarily left to the manufacturers. In the development of new drugs, the 
14 
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manufacturers would propose prescription or nonprescription status within their new 
drug application which was submitted to the FDA.(7,22,24) This legislation ignored 
some important issues. Although the act stated that drugs sold by prescription were 
exempt from some labeling requirements, it did not specifically differentiate between 
prescription and nonprescription status for drugs. In other words, there was no mention 
of which drugs could be sold by prescription or which drugs could not be sold without 
one.(7) This allowed drug companies to create a class of drugs which could not be sold 
legally without a prescription. This process curtailed consumer access to drugs since the 
FDA and manufacturers would decide from what products they could select. This goes 
against what the FDA proposed or hoped to achieve by the initial enactment of this 
legislation. 
The FDA still had a legitimate concern about some of the potentially harmful 
substances which were accessible to consumers without supervision of a physician or 
sufficient labeling to assure their safe use. Since none of the regulations was applicable 
to the drug products which entered the market prior to i938, a range of products whose 
safety was never subject to FDA approval or review remained accessible to 
consumers.(22,24) Also, as mentioned earlier, prescriptions were not needecl to purchase 
any nonnarcotic drug. This situation revealed the lack of definitive guidelines or 
operational rules available to the FDA for consistent decision making. 
From 1938 through 1951 , with the implementation of the FDA approval system, 
two classes of medicines were evolving without recognition. Newly developed drugs or 
drug products which were subject to FDA apporval were forming a class which required 
15 
physicians' orders while existing drug products remained directly accessible to 
( consumers. The terms prescription and nonprescription had not been applied to label 
either class of medicines. (7) An additional inconsistency was recognized by legislators. 
Two manufacturers could have similar products with the same ingredients. One 
manufacturer may have been subject to placing the drug under limited access as a result 
of the approval process, while the other was able to market its product without any 
restrictions and thus be directly accessible to consumers. The timing of when each 
product was developed and marketed, compared to whe~ the new regulations were 
imposed accounted for this discrepancy.(22) Between 1944 and 1951 regulators became 
aware of the fact that there was little uniformity within the drug marketplace. The 193 8 
FD & C Act laid down the framework for the initial organization of the nonprescription 
and prescription market but left a number of issues to be addressed with further 
regulatory developments. 
D. Durham Humphrey Amendments of 1951 
In 1951, the FDA proposed some additional general guidelines which would 
create broad parameters for categorization of drug products, thus providing an 
. . 
opportunity to clear up market inconsistencies. The Durham-Humphrey amendments 
encompassed these changes and marked the beginnings of a clear distinction between a 
prescription and nonprescription class of drugs.(7,9) The FDA wanted to make all safe 
and not misbranded or mislabeled medicines accessible to consumers. Those medicines 
falling into this category would be classified as nonprescription. Any medicine which 
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bore the "Caution Legend" and required use under medical supervision would be 
( considered prescription.(15) Three provisions in ·the ·nurham-Humphrey amendment 
described the criteria which were to be applied toward determining prescription 
classification. ( 4, 7,21) 
1. Habit-forming drugs that are specifically identified in section 502( d) of the FD & C 
Act. (includes seventeen drugs and their chemical derivatives in this category)(32,35) 
2. Any drug which "because of its toxicity or other potentially for harmful effect, or 
method of its use, or the collateral measures necessary to its use, is not safe for use 
except under the supervision of a practitioner licensed by law to administer such 
drug." (32,35) 
3. A drug which "is limited by an approved application under section 505 for use under 
the professional supervision of a practitioner licensed by law to administer such 
drug." "New drugs," as defined in section 201 of the FD &C Act are approved by an 
application under section 505 of the FD & C Act. (32,35) 
The enforcement of the distinction between prescription and nonprescription was left to 
pharmacists in their role as a gatekeeper of medicines. Those pharmacists who sold 
prescription medicine as Over-the-Counter medicine could be prosecuted for 
misbranding, but the courts would sue the manufacturers for not placing the appropriate 
. 
prescription or nonprescription designation on the medicine. (24) 
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Another effort toward achieving uniformity of the marketing status of products 
was focused on those drug products which contained the same ingredients for similar 
purposes. All drug products with similar ingredients were placed in the same 
prescription or nonprescription class.(22) These changes began to enhance regulation 
patterns of drug products but did not have a profound 'impact in the FD A's process of 
determining which drugs should be prescription or nonprescription. 
E. The Kefauver-Harris Amendments of 1962 
In 1960, the drug company William S. Merrell, submitted a new drug application 
to the FDA for a drug known as thalidomide.(3,23) The application was returned by the 
FDA to Merrell on several occasions due to the insufficient safety information.(24) At 
the same time, in Germany and other European countries, a serious condition called 
phocomelia appeared at a startling rate.(24) This teratogenic condition caused numerous 
children to be born with missing extremities such as. hands or feet. It was soon 
discovered that thalidomide was the culprit for these birth defects and the drug was 
removed from the market. The new drug application to the FDA for thalidomide was 
removed without approval for use in the United States. (24) Although thalidomide was 
never approved here, it was distributed in the United States for clinical testing. This was 
allowed because the FDA had no authority under the 1938 FD & C Act to supervise 
clinical drug testing. The result of this testing was a small but alarming outbreak of 
phocomelia in this country.(23) 
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As is often the case, history had to repeat itself in order to achieve progress in 
the regulation of drugs. During the thalidomide controversy, . Senator Kefauver 
proposed a bill to increase FDA surveillance over drug manufacturing and new drugs, to 
increase competition between drug companies. A more important section of this bill 
called for an addendum to the safety requirement of drugs. Kefauver proposed that this 
requirement should include efficacy and evidence of this should be included in new drug 
applications submitted to the FDA.(4,24) The Kefauver-Harris amendments of 1962, also 
known as the drug efficacy amendments, were pas.sed by Congress for the purpose of 
applying more stringent criteria to all drugs, both prescription and Over-the-Counter. 
Drugs were expected to be proven effective for their proposed claims and safe for their 
labeled use.(15) These amendments forced the FDA to reevaluate all drugs that had been 
previously approved based on safety alone. 
The FDA reviewed approximately 4,000 drugs.(5,22) Most of these were 
prescription-only status. Only 512 drugs were OTC products; of these 25 percent were 
deemed effective. (22) With this finding, the FDA recognized the need for a major 
revamping of the structure of the OTC market. Since it was well known that an 
abundance of products comprising the OTC market. we~e never subject to approval, the 
FDA embarked on a tremendous but important task of reviewing all OTC products. This 
came to be known as the OTC Drug Review. 
These 1962 amendments made important changes in the regulation of existing 
drugs. They forced manufacturers to conform to good manufacturing procedures, place 
generic names in addition to the trade name on package label, and be ready to undergo 
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frequent inspections by the FDA. (18,19) The amendments also affected the FDA itself 
by giving the FDA the ability to withdraw previously approved NDA applications based 
on insufficient evidence of safety and/ or efficacy. ( 18, 19) The law applied to any and all 
drugs, even those marketed prior to 1962. These regulations appeared to be a cure-all in 
the regulatory end that would now prevent mishaps from recurring . . But in the case of 
thalidomide, safety or effectiveness was not disputable then or now. The issue of 
controlling potentially harmful drugs which meet the safety and efficacy requirements 
had yet to be addressed. Over time, the solution emerged from the vast amounts of 
scientific evidence the FDA required for NDA approval. 
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IV. The OTC Drug Review 
( 
In 1972, the FDA along with several scientific panels began the most significant 
and complex endeavor to regulate Over-the-Counter medicines. After many years of 
addressing the issues of safety and effectiveness . and creating a distinction between the 
. 
prescription (or legend) and nonprescription classes, the FDA launched the-Over-the 
Counter Drug Review with the objective of achieving uniformity in the OTC market. 
The review process took approximately twenty years for the FDA to complete. 
(5,16,22) 
In the initial phase of the review, the OTC drug advisory panels set out to 
evaluate all OTC products for their safety and effectiveness, and the labeling conditions 
which ensured this standard. The first goal of this review was to eliminate products from 
the market which did not measure up to the standards of safety and efficacy. A second 
goal was to assess the products for misbranding or mislabeling. (5,22) 
To accomplish these goals, the panels . classified ingredients into three 
categories:(5, 7,21,22,3 7) 
Category I- generally recognized as safe and effective for the-claimed 
therapeutic indications; 
Category II- not generally recognized as safe and effective or the 
the indications were unacceptable; 
Category ill- insufficient data available to permit final classification. 
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Recognizing the amount of time required for reviewing the thousands of drugs on 
the market, the FDA elected to organize and condense the review process by developing 
tangible regulations in the form of monographs for the therapeutic categories of products 
encompassing the OTC market.(5,22) The decisions on the categorization of ingredients 
were published in the Federal Register for review by the manufacturers.(5) If a 
manufacturer found its ingredients in category II or m, it was granted limited time to 
reformulate the products, or carry out further studies to ~stablish safety and effectiveness 
for the claimed therapeutic indications. If the company could not meet the designated 
criteria, it had to remove its ingredient from the market.( 4,5) 
The Tentative Final Monographs, which eventually became Final Monographs, 
contain information defining the conditions of use of specific drugs which would be 
generally recognized as safe and effective. To avoid misbranding or mislabeling, the 
monograph also provides guidelines for packaging and labeling, the approved dosage 
forms, the composition of the formulations (essentially the active ingredient or 
combination of active ingredients), the proposed dosages and directions for use, and any 
necessary warnings which assures the safe and proper use of the product. It was possible 
. . 
to extend a monograph to include testing procedures if warranted.(22) Once an OTC 
monograph was created, it was codified in the Code of Federal Regulations.(22) At that 
point, manufacturers could market a product without prior approval by the FDA as long 
as that product complied with the guidelines in the appropriate monograph.( 4,5) 
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V. Methods of Switching Products from Rx (Prescrip'tion) to OTC Status 
The summary below outlines the methods and their applicable circumstances 
which have been established for switching prescription-only medicines to Over-the-
Counter status. The discussions which follow describe the conditions for each method. 
1. Petition to amend an OTC Monograph 
- manufacturers, professional organizations, consumers 
- OTC Drug Review Panel recommendations 
- FDA proposed (under Switch Regulation) 
* prescription medicines to OTC status 
* revision or reformulation of an OTC product 
2. New Drug Applications or Supplemental New Drug Applications 
- manufacturers who are NDA holders of potential switch ingredients 
* prescription medicines to be switched to OTC (same dose/indication) 
* prescription medicines: a new indication or a change in dose to be 
switched 
* new OTC medicines 
* revision or reformulation of OTC product 
3. Abbreviated New Drug Application 
- manufacturers 
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* for prescription or OTC generic drugs 
*prescription medicines to be switched to OTC: change from Rx use to OTC use 
*ANDA method not used in switch process 
A. The Switch Regulation (21 CFR 310.200,1956) 
The Switch Regulation, employed by the FDA, allows the commissioner or any 
interested party, usually a manufacturer, to submit a petition to exempt a drug from its 
limited access of prescription status as specified under its NDA.(37) This process will 
lead to the switching of this drug to OTC status if the FDA determines that the 
limitations for dispensing are unnecessary for the protection of the public health. This 
regulation has been utilized by the FDA to switch approximately 25 ingredients to OTC 
status. ( 5) Most of these product have fallen into the cough and cold and sleep aid 
categories. 
During the OTC review, the panels also reviewed several prescription products 
for possible OTC use. In addition to proposing that certain over-the counter medicines 
be switched to prescription status, they proposed 31 prescription-only medicines to be 
switched to OTC status. These recommendations for switching from the -OTC review 
panels received favorable support from the FDA, since it approved 18 of the proposed 
switch ingredients.(5,22,37) 
The FDA initiated several prescription to OTC switches itself Under the FDA's 
Switch Regulation, the FDA may use its authority to switch prescription only products 
to over-the-counter status based on its own decision or on petitions from manufacturers. 
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(5,37) One example of an FDA initiated switch was in the case of the drug 
metaproterenol, a bronchodilator. In 1982, when the FDA published the bronchodilator 
tentative final monograph(TFM), it chose to include the drug metaproterenol as an 
approved ingredient as a bronchodilator for inhalation.(5) Since epinephrine existed on 
the OTC market in both oral and inhalation forms, the FDA felt metaproterenol could 
offer similar or possibly better therapeutic benefits with no more risk than 
epinephrine.(5) This was the first time the FDA switcheCl a drug without consulting with 
their OTC drug advisory panels. In 1983, the OTC products containing metaproterenol 
appeared on the market. While excessive complaints were filed with the FDA from 
physicians regarding their concern about the safety of this drug as an OTC product, the 
FDA consulted with the Pulmonary-Allergy Drug Advisory Committee about the switch. 
The committee voted to rescind the decision of switching this drug because of the 
potential adverse effects which could occur with misuse, and the reversal to prescription 
status was announced soon after.(5,37) This was the last time FDA used its authority to 
switch a drug without consulting with its scientific panels.(5) 
B. Petition to Amend the Monograph Method 
Manufacturers, regulatory agencies, or any interested party can petition the FDA 
to amend the Final OTC monograph to include another ingredient for OTC use, based on 
the indication(s) specified in a therapeutic category.(5,21,37) This method may be used 
for prescription drugs with potential for OTC marketing, reformulation of an OTC 
product, or a change in the indication of an OTC product. Manufacturers can not utilize 
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the petition method for a "new drug." A "new drug" is one which is not generally 
recognized as safe and effective (GRAS/GRAE) under the condition prescribed, 
recommended, or suggested in the labeling.(1,26,35) Products that meet specifications in 
a final monograph are expected to have a marketing history for "material time and to a 
material extent."(1 ,11,21) Material time and material extent refers to at least three 
years of marketing time and relatively high use of a drug during that time.(1,21) 
Marketing a drug as a prescription for at least three years permits sufficient data to be 
collected through ADR reports or revisions in labeling made by the manufacturer due to 
the occurrence of ADRs.(1) The petition method is not recommended because the FDA 
applies more stringent standards in its decision and . it tends to be reluctant to change 
expert scientific information which was integrated over an extended period of time. ( 11) 
For manufacturers, there are some drawbacks in using with this method. Particularly 
worrisome to the manufacturer is that the submitted information will be publicly 
available. Also, there will no marketing exclusivity, and the evaluation time period is 
expected to be extensive.(11) 
C. New Drug Application Method (NDA) 
Since the OTC drug review began in 1972, several drugs have been switched by 
the New Drug Application or supplemental New ·Drug ~pplication methods. The NDA 
method requires manufacturers to submit complete safety and efficacy data.(11) A drug 
which is switched by the NDA method is subject to postmarketing surveillance. 
(1 , 11 )Compared to the other methods of switch, the NDA route seems to be the most 
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expeditious, since the time for review of the application by the FDA and the scientific 
panels has been on the average of two to three years. A manufacturer's petition to 
amend a monograph may take several years.(11) . 
Provided their product has a reputable and lengthy market history (as a 
prescription), manufacturers usually proceed with the switch process by the NDA 
method. The basic criteria considered, as stated by the FD & C Act, is that the 
ingredient must not be habit forming, must be safe and effective without needing medical 
supervision, and finally has adequate labeling.(1,7,9,37) 
Through the NDA method, manufacturers reserve the possibility of obtaining 
marketing exclusivity depending on whether they include "essential" clinical information 
from new clinical investigations with their application. (11) This exclusivity may be 
granted according to the terms of the Drug Price Competition and Patent Restoration 
Act of 1984.(11) If the FDA does not require this ·clini'cal data, the likelihood of being 
eligible for this exclusivity is lessened. This is worrisome for manufacturers because if 
no exclusivity is granted, other NDA or ANDA holders could submit labeling 
supplements to the FDA and quickly enter the OTC market as competitors.(11) 
Another benefit available to a manufacturer filing an NDA is the potential 
confidentiality offered to the manufacturer prior to the final approval stages.(11) This 
ensures the manufacturer that it will lead the market in the specific product line with its 
OTC product. 
27 
( 
( 
D. Abbreviated New Drug Application (ANDA) Method 
An ANDA application as the name denotes is a condensed form of an NDA. 
With this application, the drug company is responsible for referencing complete safety 
and efficacy data but it does not have to be the one who conducted the studies.(! I) The 
ANDA has been most commonly utilized by generic companies interested in entering the 
market at or close to the time of patent expiration of prescription and nonprescription 
products. The FDA has implied that this application may be used to switch a drug from 
prescription to nonprescription, by proposing a change in the indications for use.(! I) To 
date, this method has not been officially integrated into the switch policies; therefore, it 
is yet to be used by a manufacturer for a switch. 
VI. Nonprescription Drug Advisory Committee (NDAC) 
In 1991, the FDA appointed several individuals to a committee known as the 
Nonprescription Drug Advisory Committee (NDAC).(14) These appointees represent 
expertise from the health professions (doctors and pharmacists), the industry, the 
regulatory agencies, and the consumer population. Their primary responsibility is 
advising the FDA on decisions regarding Rx-to-OTC switch NDAs and petitions.(14) 
The committee is also responsible for informing the FDA of developments in the Rx-to-
OTC trend and self-medication.(14) They serve as an important liaison between the FDA 
and the industry, health care professionals, professional organizations, and consumers. 
The development of the NDAC committee is another effort the FDA is extending 
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towards maintaining the progress of the Rx-to-OTC Switch trend, enhancing self-
( medication, and controlling the over-the-counter market. 
VII. Summary 
The government has invested a great deal of time and expense in evaluating 
numerous drugs in order to provide consumers with safe and effective Over-the-Counter 
products. Consumers have long expressed to the industry and government regulators 
their concerns about drug safety, effectiveness, cost, availability, and the freedom to 
choose. The FDA addressed some of these concerns and implemented several laws 
. . . 
designed to meet consumer needs. 
When it comes to self-health care, consumers have repeatedly demonstrated a 
positive interest and willingness to assume an active and responsible role. National 
studies have documented this interest, as well as the habits for self-medication with OTC 
medicines. Consumers recognize that minor ailments or conditions can be safely and 
effectively treated with OTC medicines.( 4) They appreciate the direct access they have 
to these medicines since it saves the time and money involved in visiting a physician. 
With the advent of switching drugs from prescription to Over-the-Counter status, 
consumers will have more options available to use in self-care. 
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I. Introduction 
Improving Self-Medication With Rx-to-OTC 
Switch Medicines 
Looking back through history, we can observe a pattern in regulation that 
developed as a response to consumer demand for safe and effective drug products. The 
consumer has played an integral role in guiding the government towards higher standards 
of safety for medicines, healthy competition in the industry, and maintaining the freedom 
to employ self-health care. 
A previous paper (manuscript I) outlined the legislative drug history and 
portrayed the sequence of events that caused regulators to exercise control over the 
drug market. An original goal of the regulations was to provide consumers with safe 
drugs. Over a lengthy period oftime, the regulations were expanded to address the 
efficacy of drugs and the sufficiency of product labeling to promote safe and proper use. 
Although the Food and Drug Administration (FDA) always focused on preserving the 
consumer's freedom in choosing their own medicines for' self-treatable conditions, the 
regulations gradually adopted, affected this choice by limiting the medicines available 
without the intervention of a physician. Over time, the Over-the-Counter (OTC) market 
was restructured to contain a broad selection of safe and effective medicines, restoring 
the choice of the consumer. 
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( II. Background of the Rx-to-OTC Switch Trend 
The switching of prescription products to Over-the-Counter products is not a 
new phenomenon. It was stated as early as the 193 8 FD &C Act that drugs were to be 
made available to the public without a prescription if they presented no potential safety 
concerns. Thus, the process of switching drugs from prescription status to OTC status 
reinforces the goal of making more drugs available to the consumer. The OTC Drug 
Review panels and the FDA developed the Rx-to-OTC switch process which today, is 
the predominant procedure used for switching products. Presently, there are many drugs 
on the OTC market that contain active ingredients previously available by prescription 
only. With the switch policies now in place (NDA, Switch Regulation, petitions to 
FDA, manuscript I), manufacturers are cautiously proceeding in proposing their 
prescription drug products for the switch to OTC status. 
When the OTC Drug Review commenced in the early 1970s, the process for 
restricting the sale of drugs slowly began to be restructured towards removing the 
restricted status on any safe and effective medicines. The FDA and several scientific 
panels reviewed numerous OTC medicines and organized them into therapeutic 
categories. Monographs, which referenced approved active and inactive ingredients, 
indications, dosage forms, and proposed labeling, were created for each therapeutic 
category. These monographs stated the guidelines for manufacturers to follow in their 
development of new drug products and/or reformulation of previotisly, or currently 
marketed products. 
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One of the important achievements of the OTC Brug Review was the initiation 
of switching some prescription products with established safety histories, to OTC status. 
The OTC Review panels were given the authority, by the FDA, to switch ingredients 
from either status (prescription or nonprescription). Under the Review procedures, 
most of the switches recommended by the panels were OTC drugs to be switched to 
prescription status because of safety and labeling questions. The panels also 
recommended 27 prescription drug ingredients to be switched to OTC status. The FDA 
approved 18 of them under the Switch Regulation.(6) Since the OTC Review began, 
approximately 50 ingredients have been switched from prescription to nonprescription 
status by the FDA.(11) Listed below are a few of the early switch products resulting 
from the Review. 
Ingredient 
brompheniramine 
maleate 
doxylamine 
succinate 
oxymetazoline 
hydrochloride 
T I 1 
Early RX-to-OTC Switch Products 
Product category Date of approval 
antihistamine Sept.9,1976 
sleep-aid Oct. 18,1978 
nasal decongestant Sept. 9, 1976 
Tradename(s) 
Dimetane 
(AH.Robins) 
Unisom 
{Pfizer) 
Afrin( others) 
(Schering) 
Source-Nonprescription Drug Manufacturers Association, Washington,D.C.(Nov. 1991) 
This progressive step began to restore the power of choice to the consumer and 
to allow him to play an active and responsible role in self-medication. Not only does the 
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consumer now have an increasing ability to choose but also a continuously broadening 
selection of safe and effective drugs to choose from. 
Self-care is of increasing interest to the public, and self-medication is an essential 
component in self-care. By placing more safe and effective OTC medicines on the 
market, the FDA provides consumers with the possibility of improving self-care. 
However, as more medicines become available without a prescription, it must be 
recognized that they may be accompanied by more risks to the consumer. The challenge 
now will be how the institutions-government, manufacturers, public organizations, 
advertisers and health care professionals, will meet their responsibilities to provide the 
necessary information to consumers for good decision making. This information must be 
conveyed in a clear, concise, yet sufficiently detailed manner directly to consumers. 
ID. Rx-to-OTC Switch Products 
Within the last few years, the approval of Rx-to-OTC switches has resulted in 
significant expansion of the OTC market. This is only the beginning, since some of the 
future candidates considered will lead to more dramatic changes to the increasing and 
widening selection of over-the counter medicines. The two following tables present both 
recent Rx-to-OTC switch approvals and future candidates being considered 
respectively. ( 12) 
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Recent Rx-to-OTC Switch Ingredients 
Ingredient Product category Date of approval Method Tradename 
clotrimazole antifungal Oct. 23,1989 NDA Lotrirnin AF 
1% topical Schering 
clotrimazole anticandidal Nov. 30,1990 NDA Gyne-Lotrimin 
1% vaginal use Schering 
hydrocortisone antipruritic Aug. 30, 1991 FDA Cortaid-Max 
0.5-1% Upjohn 
rniconazole anticandidal Mar. 13, 1991 FDA Monistat 7 
nitrate 2% Ortho 
ibuprofen analgesic May 18, 1984 NDA Advil 
200mg Whitehall 
permethrin pediculicide May 5, 1990 NDA Nix 
1% B.W. 
ketoconazole shampoo Feb. 16, 1994 NDA 
1% dandruff J. & J. 
naproxen analgesic Jan. 1994 FDA Al eve 
anti-arthritic Syntex 
loperarnide anti diarrheal Mar. 3, 1988 NDA Imm odium-
HCL ADJ.&J. 
salicylic wart remover Oct. 1991 FDA Duofilm 
acid Schering 
Source:Nonprescription Drug Manufacturing Association, Washington, D.C. (Nov. 1991) 
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Table 3 
Current Rx-to-OTC Switch candidates 
Ingredient Product category Status/Method 
acyclovir cold sore pendingNDA 
cimetidine antacid pendingNDA 
sucralfate anti-ulcer pendingNDA 
famotidine anti-ulcer pendingNDA 
methocarbamol muscle relaxant pending NDA & petition 
terfenadine antihistamine pendingNDA 
erythromycin antibacerial pending FDA 
diflunisal analgesic pending FDA 
nystatin antifungal not cited 
Source: Nonprescription Drug Manufacturers Association. Washington. D.C. (Nov. 1991) 
IV. Future Considerations for Rx-to-OTC Switch 
The list below are some prescription drug ingredients/categories and their 
indications that will be considered for switch in the near future.(12) 
beta blockers - nervous tension/stage fright 
beta-2 agonists- wheezing bronchitis · 
cromolyn sodium-allergic/ exercise asthma 
dicyclomine- irritable bowel syndrome 
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promethazine-antiemetic 
piroxicam- analgesic 
methenamine-genito-urinary( e.g. U . T .Is). 
V. Criteria for Potential Switch Candidates 
A. The FDA perspective 
Before a drug may be considered a candid.ate for Rx-to-OTC switch, it must 
meet the criteria established by the FDA for three general categories: safety, efficacy, 
and labeling.(2,6, 14) 
There are two chief concerns under the safety category and these include toxicity 
and collateral measures necessary for use. Within the toxicity section, there are four 
particular issues which must be addressed by the manufacturer. The first of these issues 
involves the assessment of the overall margin of safety of a drug and its potential to 
cause harmful effects, both of which must be supported by clinical pharmacological 
data. The manufacturer must assess the incidence and degree of adverse drug reactions 
that can occur or has been associated with the use of the.drug. If the drug will be subject 
to use by special populations such as pregnant or nursing women, the elderly, or 
children, the safety for these populations must be given special attention. (14) 
The second issue pertains to the benefit/risk assessment of the product when used 
according to the directions for use and warnings for unsafe use. (14) It is expected that 
every drug will have both benefits and risks, and in order to receive the benefits it is · 
necessary to tolerate a certain degree of risk. The manufacturer must show that the 
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benefits from a drug are greater than the risks involved, and must develop adequate 
labeling that can inform consumers about the ways to reduce the potential risks while 
benefiting from the use of the drug.(14) 
The third issue addresses the potential safety problem that may arise from drug 
misuse/abuse. The manufacture must establish the margin of safety with respect to the 
possible misuse or abuse of the drug. (2,14) It must demonstrate that the drug is still 
sufficiently safe even when misused either for a condition not included in the indications, 
or by a person with a serious disease condition such as diabetes or hypertension. The 
last issue questions whether medical follow up or laboratory testing is necessary with the 
use of the drug.(14) Such a requirement would make the' drug unsuitable for the OTC 
market. 
Four questions arise when addressing the issue of collateral measures that may be 
necessary to use with a switch drug. (2, 14) 
1.) Can the condition for which the drug is indicated for be self-diagnosed? 
2.) Are the symptoms associated with the condition self-recognizable? 
3.) Is the condition self-treatable? 
4.) Is medical intervention (lab tests, exams) necessary as the patient continues 
to use the drug? 
These questions must be considered and resolved by the manufacturer in their switch 
proposal. This area is of utmost importance to the FDA when considering the switch of 
a drug, and is the most challenging for the drug manufacturer to support scientificly. 
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Efficacy refers to the requirement that the drug proposed for switch achieves the 
claimed effect, and it will do so to the same degree as the prescription form of it when 
used under the same conditions. (21 ,22) The manufacturer must support the claimed 
indication with clinical data. If there is an anticipated change in dose or modification in 
the formulation for the drug to be switched, the manufacturer must document that these 
changes do not alter the safety and efficacy profiles for the drug. They should be 
prepared to support this with data.(14) 
The labeling proposed by the manufacturer must include adequate directions for 
use, warnings against unsafe use, side effects, adverse drug reactions, duration of use 
limitations, and advisement on seeking medical attention. This information must be 
clearly readable and understandable for people with low comprehension.(21) 
These criteria established by the FDA are intended to provide the manufacturer 
with sufficient guidelines in order to determine whether their prescription drug product 
will be marketable as an OTC product. 
B. The Industry perspective 
The industry initially approaches the switch of a drug with a perspective different 
from the FDA. Before the drug company begins to assess is product for the criteria set 
by the FDA, it first evaluates the candidate from a marketing point of view. Consumer 
demand and need for the product must be considered before a business commitment will 
be made.(7) Developing new OTC drug products is challenging to the manufacturer 
primarily because the product's success is dependent on ~onsumer need and demand. 
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Sufficient marketing analysis for consumer interest and intent of purchase must be 
completed before proceeding with the actual development. (7) With an Rx-to-OTC 
switch product, the failure rate in the OTC market is minimized because the product 
already has an established history with consumers, physicians, and pharmacists.(7) 
Therefore, the support base from health care professionals and consumer interest can 
only be increased. The Rx-to-OTC switch process allows drug companies to target a 
wider audience with newly available products and to build a stronger rapport with the 
health care profession. 
From a business perspective, a drug company will consider the product's ability 
to generate sales and profits. (14) Ideally, in marketing a switch product, a manufacturer 
hopes to rejuvenate the life cycle of the prescription form of the product. Usually, after 
a long marketing period as a prescription product, the interest and sales for it decline. 
This may be attributed to the development of new drugs or aggressive promotion by 
other manufacturers. After switching the product to OTC status, the drug company 
essentially creates a new product and the life cycle of the product begins again.(14) The 
last incentive for the manufacturer to switch a product is'to extend a product's patent 
protection under The Waxman-Hatch Act, provided the FDA requires new clinical trial 
data. (14) Since generic competition is strong in today's nonprescription and prescription 
drug markets, drug companies which hold NDAs to prescription drugs that are 
approaching patent expiration must take advantage of this opportunity to preserve 
exclusivity for three additional years.(14) The revision of the NDA or supplement to the 
NDA will encompass a change in specifications for use (as an OTC product) and include 
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new clinical data. This will guarantee the manufacturer protection from abbreviated 
New Drug Application competition. 
At this point, the manufactuer will proceed with tarduous task of collecting the 
required scientific evidence for the switch proposal, whether it is in the form of an NDA, 
a supplemental NDA, or a petition . 
VI. Economic benefits evolving from the Rx-to-OTC Switch Trend 
The tables of switched drugs and those considered for switch, demonstrate the 
major changes occurring in the OTC market. As a result, consumers experience 
improved yet affordable opportunities for self-care. Rx-to-OTC switch drugs have 
already made a dramatic impact on consumer and national health care costs. Since cost 
is a major factor in the nation's current health care predicament, the cost savings 
associated with self-medication has been a significant factor in promoting this issue. 
The tradition of visiting a physician for minor ailments or even more serious 
conditions has become less common for many consumers. John Naisbitt states in his 
bookMegatrends: Ten New Directions Transforming Our Lives," 75 percent of the 
people can successfully deal with medical problems without ever walking inte a clinic or 
doctor's office." Studies have shown that the number of doctor visits have been falling 
steadily over the past twenty years. In 1989, 1.65 million fewer MD office visits for the 
treatment of cold symptoms were made as compared to those in 197 4. ( 16, 17) These 
figures may be accounted for by the following: the consumer's overall economic 
situation, whether or not they have insurance to pay for the doctor visit and/or 
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prescription, or their desire to self-treat with OTC medicines. Consumers who do not 
want to take time from work because of the loss of pay or the risk of losing a job, will 
often opt for self-treatment with OTCs. A final contributory factor involves consumers 
requesting doctors to prescribe medication over the telephone for recurring conditions 
that are recognizable to the patient. 
The average doctor visit has been determined to cost $40. 00. ( 1, 16, 17) Additional 
to this expense is the travel to the office, and the cost of a prescription, if not covered by 
insurance. The average prescription price is now approximately twenty dollars.(16) 
The time spent to complete the doctor visit is costly as well. The consumer has to take 
time out of work for travel and to spend time waiting to be seen by the doctor. Often, 
this time is viewed by the patients as excessive because physicians are trying to maximize 
their income by seeing more patients. On the other hand, the cost of a typical OTC 
product is $4.00, and it requires only a quick trip to the nearest store, whether it be a 
convenience store, supermarket, or drugstore. (16) Kline Research revealed from their 
research that OTCs saved the nation $10.5 billion in 1987. This figure includes 
prescription costs, doctor visits, lost time from work, travel, and insurance costs.(3) 
It is also interesting to see results from studies on switched products-with regard 
to the economic savings. Economist Peter Temin has determined, from an analysis of the 
cost benefits of Rx-to-OTC switch for cough and cold medicines, that consumers saved 
$770 million in 1989 alone.(16) In another example, 0.5% hydrocortisone cream, it was 
shown that the savings for the American consumer was more than $1 billion for the first 
three years it was available over-the-counter.(16) The most recent Rx-to-OTC switches 
45 
( 
( 
include Gyne-Lotrimin (clotrimazole) from Schering-Plough and Monistat 7 
(miconazole) from Johnson & Johnson. These are two examples of drugs that have been 
placed in a new class of OTC drugs for gynecological yeast infections. Sales for this 
category is expected to reach close to $150 million by the end of 1994. (2,5) Sales for 
new switches combined are expected to fall into the range of$550 million and $600 
million by the year 1996.(2) 
As can be seen from the chart provided (Figure 1 ), the least amount of money 
spent in any health related category is the over-the-counter medicines and sundries. 
According to the Health Care Financing Administration, although six out of ten 
medicines bought by consumers are nonprescriptions, spending for OTC medicines only 
accounts for 
2 percent of the nation's total health care spending. (10) 
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Figure 1 
1990 National Health Expenditures 
Hospital Care 
41% 
Physicians' 
Services 
21% Other Personal 
Health Care 
5% 
Dentist, Other 
Profs 
11% 
Admin.,Public 
Health 
13% OTC Medicines 
2% Medical Sundries 
7% 
Source: U.S. Health and Human Services Department, 
Health Care Financing Admin., Office of the Actuary 
With the continuing rise of health care costs in the U.S., Fhe government must derive a 
solution that encourages advancement in medical science but promises a reduction in 
costs on both individual and national levels. The switching of prescription medicines to 
OTC status creates the opportunity to improve self-health care economically for the 
consumers while eliminating costs in other health care categories. 
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VI. Physician perspective of Rx-to-OTC Switch Trend 
The physician population appears to be divided in its views of switching 
prescription medicines to OTC status. On the positive side of this issue, there are many 
physicians who believe that consumers do want to become their own primary caretakers 
and that they can be responsible about it. (9,23) Therefore, switching prescription 
medicines to OTC status will provide a wider selection of effective medicines to work 
with. These physicians realize that patients who use OTCs for minor ailments rather than 
checking with them spontaneously, generate extra time the physicians can use for 
patients who are suffering more serious conditions. The physician, aided by the 
limitations of self-medication, can also save time and exp'ense for the patient with 
unnecessary diagnostic testing or inappropriate prescription medications ifthe use of 
appropriate OTCs has not provided significant improvement.(9,23) 
Depending on their practice or field of specialty, physicians commonly prescribe 
OTC medicines for patients in several different circumstances. National Center for 
health statistics revealed from its survey that one of every eight drugs prescribed or 
recommended by physicians in 1985 was an OTC drug. (1,3) These may include: 
recommending OTCs for patients who call for advice until a follow up office visit can 
occur, recommending OTCs to relieve symptoms from minor ailments without necessary 
follow up, using OTCs to treat several gastrointestinal p~oblems,(9) and employing 
OTCs for the prevention of serious, recurring or worsening conditions (aspirin for 
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prevention of myocardial infarctions, bulk fiber for constipation/regulation, insulin for 
Diabetes). In these circumstances, OTCs are essential to provide immediate or long term 
benefits. 
The other perspective held by some physicians is that patients are not informed 
enough to be held responsible for their own self-care, and this appears to be a consistent 
opinion among many physicians. Physicians feel that switching prescription medicines to 
OTC status is detrimental to their patients' health, and a potential hindrance to their 
practice. (23) It is difficult to deduce whether the patients have demonstrated this to 
them through habits, or that physicians believe a sophisticated level of knowledge is 
required to self-medicate effectively which is beyond the level of most lay people. A 
further explanation is provided in Dr.Donald Vickery's "office door orientation." This 
refers to the population of physicians who are concerned only with the patients that walk 
through their doors, not with the community as a whole. It is not their interest to know 
whether the community is benefiting by the substantial advantages in cost or treatments 
offered by OTCs. To further delineate this point, Dr. Vickery feels physicians are 
concerned with the symptoms or problems presented by the patients in the office and 
those which bring them back to the office, not what the patients do outside the office 
with self-treatment for other minor ailments.(23) 
Physicians are vital components in the health care delivery system and can 
provide substantial information on patient habits with regard to medications and general 
self-care. Physicians must realize that they are in a pivotal position to promote self-care, 
and they have a responsibility to educate patients on recognizing conditions, self-
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medicating with OTCs, and diagnostic testing. However, some physicians are unwilling 
to relinquish the power that the profession has acquired over the years. Physicians have 
assumed authoritative trusting roles with patients and other health care professionals, 
and now some of them feel threatened by the behavior of the whole health care delivery 
system which is responding to patient demands for direct participation in their health care 
issues. The authority in the decision making process is undergoing redistribution to 
include other health care professionals, regulators, third party payors, and it empowers 
patients themselves. 
VIII. Pharmacist perspective of the Rx-to-OTC Switch trend 
Pharmacists are a traditional and important source of OTC medicines for 
consumers. Although, pharmacists perceive OTC drugs as safe and effective therapeutic 
agents, they recognize that he limitations of these and all other drugs are dependent on 
proper and appropriate use. Pharmacists have a great deal of experience in observing 
patient habits with both OTC and prescription medications. They continue to fulfill their 
educative responsibilities through counseling and recommending appropriate products 
for patients. Pharmacists also play a critical role in monitoring the need for patients to 
be referred to their physicians. As the professional who has the most frequent regular 
contact with patients, the pharmacist's interaction with the patient can be responsible for 
the success of a therapeutic plan. Pharmacists enjoy this important role and are proud 
that they are regarded as the most highly respected and trusted professional.(4) 
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With the advent of the Rx-to-OTC switch trend, pharmacists are finding their 
knowledge and accessibilty a necessity for patients to rely on. Patients frequently 
consult with pharmacists on the appropriate use of switch products more so than with 
the traditional OTC products. (15) A survey conducted by a Medical Economics 
Research Group, in 1989, found that three out of four pharmacists are encountering 
more consumer discussions about OTC drugs.(5, 15) For this reason, the pharmacy 
profession continues to express some skepticism on the trend of switching prescription 
medicine to OTC status. Like physicians, pharmacists are hesitant to extend to the 
patient more responsibilty for their self-care by making available more medicines for 
more self-treatable conditions. 
In 1974, soon after the OTC Review began, (early switches by the Review), 
many pharmacists and pharmacy organizations proposed to the FDA, the development of 
a third class, or transitional class, of drugs, to place newly switched drugs. This class of 
medicines could only be sold by pharmacists. It would eliminate the need for a 
prescription for the medicines, but would allow the pharmacist to maintain the control 
over who had access to them. The pharmacist would use his professional judgement, 
which would include knowledge of the patient's history and a description of-the patient' s 
symptoms, in determining whether the medicine was appropriate. Having a third class of 
drugs could also facilitate the necessary monitoring of switched drugs for a 
predetermined period of time ('transitional class'). 
The response to this proposal by regulators and consumers is negative. 
Consumer groups feel that this is an attempt by pharmacists to maintain control in sales 
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and profits. ( 6, 13, 15) The Department of Justice objected to a third class of drugs stating 
that it would restrain competition, inconvenience the consumer, depart from U.S. 
economic policy, and cause unnecessary price increases for the consumer. The Federal 
Trade Commission has also expressed a unfavorable opinion because a it would violate 
merchants' rights to partake in the sales of these products which do not require a 
prescription. (12) The FDA shows no interest in the development of a third class because 
the proposal has yet to be supported with scientific evidence to prove that pharmacist 
intervention is necessary for the safe and effective use of these drugs. ( 6, 16) More 
importantly, the FDA feels that the effort and progress made by the regulators and 
manufacturers to supply the consumers with safe and effective medicines nullifies the 
need of additional intervention. This issue has caused much debate and will continue to 
as it receives further objection. Pharmacists will not get the right to establish a third 
category of drugs until they show clinical evidence to support the need for restriction. 
Although the skepticism exists within the pharmacy profession, pharmacists are 
out in the front lines recommending and selling the switched products. Many of the 
switch products have generated enormous of sales for their stores. More importantly, 
opportunities for an increase in consumer contact, have been created and this reinforces 
the educative role they serve in the self-medication process. 
IX. Summary 
The process of switching prescription medicines to OTC status has generated 
much controversy within the health care industry. Until recently, the general attitude 
among health care providers was that consumers are not capable of administering self-
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care. However, with the changing objectives of the health care system, the concept of the 
patient with problems and the physician with the solution 1 no longer fits into these 
objectives. Thus, many physicians and pharmacists, regulators, and drug manufacturers 
have all joined forces to combine their efforts and ideas to contribute towards the 
success of switch products. The addition of many new drugs to the arena of OTCs, and 
the consideration of adding many more in the future, has caused an important issue to 
surface. This issue involves the need for tools and/or methods of relaying necessary 
information to consumers to advise them on the appropriate use of these new products 
avilable to them. These tools may be labeling, advertising, and educational programs. 
Studies have shown that the consumer relies upon labeling and advertising as two 
sources of drug information. These two sources have received much attention from 
regulators because of their important communicative and educative functions, and are 
especially essential for current and future Rx-to-OTC switch products. Since the 
labeling for these products was initially designed for pharmacists and physicians, the 
manufacturer, with the aid of the FDA, has an important task of drafting new labeling for 
their use as OTC medicines. As these medicines enter the OTC market they bring with 
them a proven alternative which may prompt consumers to experiment while 
disregarding important information for their proper use. 
The Nonprescription Manufacturers Association (NDMA; formerly The 
Proprietary Association) is an organization which deserves considerable recognition for 
its exceptional efforts, in conjuction with the FDA, in developing guidelines for 
manufacturing labeling. Additionally, it has been devoted to creating and providing 
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consumers with educational leaflets, and instructional pamphlets that advise them on 
reading OTC package labels. 
54 
X. References 
1. America. National Disease and Therapeutic Index:Diagnosis Estimates (1990). 
2. Botstein. P. Criteria for switching new molecular entities from prescrition to 
over-the-counter, Drug Information Journal 24 29-31 (1990). 
3. Business & Health Report, Special Report, (Feb 1992) 
4. Conlan, M. F. The RPh and his image, 1991 Gallup poll, Drug Topics 
Supplement 2ls (1991). 
5. Gannon, K. Switched drugs lend vitality to surging OTC mark~t; prescription to 
OTC switches, Drug Topics 135 32-34 (May 20,1991). 
6. Gilbertson, W. The OTC Drug Review- Switch Without Regulation or 
Application, Drug Information Journal 19 101-109 (1985). 
7. Haverkost, L. How Industry Assesses and Picks Suitable Candidates for Switch, 
Drug Information Journal --12. 133-138 (1985). 
8. Juergens, J. P. The FDA and Community Pharmacy:Today and Tomorrow, 
Drug Topics 88-94 (Aug. 1992) 
9. Morrissey, J.F. Switch to OTC: A Medical Viewpoint, NDMA Symposium. 
New Sources in Self-Medication, Washington, D.C. (Nov. 1,1982). _ 
10. NDMA. Facts and Figures, Washington, D.C.(1992). 
11. NDMA Issues and Perspectives, Washington, D.C. (1992). 
12. NDMA Symposium. Washington, D.C. (September 15, 1992). 
55 
I 
13. Nonprescription Drug Manufacturers Association, l 12th Annual Meeting. 
NOMA focus inl992-93 : Cost Benefits & Consumer Power, Naples, FL (March 
5, 1993). 
14. Rheinstein, P. Criteria used by the FDA to determine what classes of drugs are 
appropriate switch candidates, Drog Information Journal 19 139-142 (1985). 
15. Segal, M. Rx to OTC; the switch is on, FDA Consumer 25(2) 8-14 (March 
1991). 
16. Temin, P. Cost and Benefits in Switching Drugs from Rx-to-OTC, 
NOMA Symposium. New Resources in Self-medication, Washington, D.C. 
(Nov. I, 1982). 
17. Temin, P. Realized Benefits from Switching Drugs, Journal ofLaw & 
Economic ,35(2) 351-368 (1992). 
18. 21 U.S.C. 330.10 (a)(4)(iii)(1983). 
19. 21 U.S.C. 330.10 (a)(4)(i), (vi) (1983) 
20. 21 U.S.C. 330.10 (a)(4)(i)(1983) 
21. 21 U.S.C. 330.10 (a)(4)v) (1983). 
22. 21 U.S.C. 330.10 (a)(4)(ii)(l983). 
23 Vickery, D. M. A Medical Perspective, Drog Information Journal 19 
155-158 (1985). 
56 
( 
MANUSCRIPT ill 
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The Implications of Labeling and Advertising on the Safe 
and Proper Use of Rx-to-OTC Switch Medicines 
I. Introduction 
Labeling and advertising of Over-the-Counter medicines (OTC) are two reliable 
sources of instructional information for consumers. They serve as invaluable methods 
for the OTC industry to communicate important information regarding the safe and 
proper use of their products, and to promote their products in a competitive market. 
Labeling especially, is in part responsible for the growing use of OTC medicines in self-
care. Both methods are useful in assisting consumers in the decision making-process for 
the selection and appropriate use of a product. Several studies have shown that 
consumers depend on both labeling and advertising to familiarize and educate themselves 
about OTC medicines. The Princeton Survey Research group on their Council on Family 
Health report concluded that 91 percent of individuals who use over-the-counter 
medicines, read the labels; within this group, 98 percent of them read OTC labels when 
they buy the product the first time, and 92 percent of them read the label when they use 
a product for the first time. (1) 
With the advent of the Rx-to-OTC switch trend, consumers are now provided 
with an extensive market of stronger and more effective medicines. Until recently, the 
OTC medicines available on the market have been useful to mitigate or alleviate 
symptoms. The Rx-to-OTC switch process has added potent medicines which cure and 
potentially even prevent minor conditions. The labeling and advertising of these 
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products is essential to ensure the appropriate and safe use. With the assistance of the 
FDA, professional associations, and consumer groups, manufacturers have the task of 
drafting new labeling for these products. They are responsible for correlating the 
information in the corresponding advertisement to the package labeling in order to 
comply with guidelines set by the regulatory agencies. 
The difference between labeling and advertising lies in the function of each. 
Labeling provides consumers with information they need' to use an OTC medicine safely 
and effectively. Advertising alerts consumers to the self-treatable nature of specific 
symptoms and moreover, it introduces the products to use to treat the problem. It is 
expected of advertising to promote and support the designated use of a product based 
upon the label claims. (3,5) Both sources should communicate identical information 
regarding approved uses and any essential warnings in order to comply with regulations 
and ensure proper use of OTC products. Manufacturers must be cautious in how 
symptoms which relate to a self-treatable condition are presented in an advertisement 
because the nature of the advertising can make the labeling of the same product 
inadequate.(?) This can happen through the message re~eived by consumers to be 
misconstrued, resulting in the incorrect use of a product. Therefore, the label 
information will not provide sufficient directions and/or warnings for the misinterpreted 
purpose. 
This paper will address the labeling and advertising issues for Over-the Counter 
medicines by presenting a review of the guidelines devised by regulatory agencies and 
implemented through legislation. Some new developments in the labeling of certain 
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OTC products will also be presented. Additionally, a discussion of how these educative 
tools are necessary for promoting the safe and proper use of recently switched drugs and 
future switch candidates. 
II. Labeling 
A. Regulatory Review 
The Federal Food, Drug, and Cosmetic Act of 1938 mandated manufacturers to 
demonstrate the safety of a drug when used according to the conditions described in the 
labeling. The term "labeling" refers to the written or graphic material which is placed on 
the container or any of its wrappers which accompany the drug product. The label 
information was to include the contents of the product and adequate directions for use in 
language understandable by persons of ordinary intelligence.(14) The 1938 Act also 
required manufacturers to place an inclusive warning on a drug product if it contained a 
narcotic or hypnotic agent. ( 11, 13) If a manufacturer determined that its drug product 
could not be adequately labeled for use by consumers, it was exempted from the labeling 
requirement, but placed under restricted access and available through pharmacists and 
physicians only. The physician would prescribe the drug and the pharmacist would be 
responsible for labeling the drug with directions understandable to the consumer. These 
actions served as the basis for the future developments in the labeling area. 
B. Labeling guidelines 
The goal of labeling is to provide sufficient and comprehensible information 
consumers need to use OTC drug products safely, correctly, and without professional 
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supervision. The challenge encountered by manufacturers is to provide this information 
in a readable and clearly understandable fashion. The label is supposed to include the 
following basic information: (7,8) 
1) The name and identity of the product 
2) What the product can be used for 
3) Contents of the package; dosage form and how many 
4) Active ingredients 
5) Inactive ingredients 
6) Directions for use, time limits for use 
7) Side effects, precautions 
8) Contraindications, warnings 
9) When to seek medical attention 
10) Manufacturer name and address 
11) Expiration date and batch code 
12) Label "flags" 
1) The name of the product- The largest print on the package label will enable the reader 
to immediately identify the trade name, generic or chemical names, and classification of 
ingredients, e.g. Product Allergy- antihistamine: chlorpheniramine. 
2) Claims or indications- The manufacturer must reference only the FDA approved 
claims or indications for the drug ingredients. It must be in a clear and concise 
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presentation. Some manufacturers associate the ingredient with the assigned indication, 
e.g. dextromethorphan (cough). 
3) Contents of package- It should be displayed clearly what the package contains 
including the net quantity, the dosage form, and the use of a tamper resistant seal. 
4) Active ingredients- These ingredients are essential to inform health care professionals 
and consumers so they can determine proper use of a pr~duct, potential drug 
interactions, or allergies to the product. 
5) Inactive ingredients- These ingredients (from United States Pharmacopoeia or 
National Formulary) must be included to aid consumers in identifying ingredients with 
which they may have an allergy to, e.g. dyes, starch, flavors, or sugar coatings. 
6)Directions for use- The manufacturer must clearly instruct the patient in the dose, 
specifically, how much (1 tablet or teaspoon) and the frequency of administration, how 
often (every 4 hours, no more than 4 doses per day). This information may be written or 
illustrated with symbols. Dosing accessories may be included to help consumers 
accurately measure liquid quantities. 
7) Side effects and precautions- Any potential side effect, such as drowsiness, nausea, or 
diarrhea, which may debilitate or endanger the user to any degree, must be listed. 
Precautionary statements may include: time limit for product use, "keep out of reach of 
children", advisory information in case of accidental overdose, or recommendations for 
the proper use of the product. 
8) Contraindications- This section oflabeling references specific drugs or conditions in 
which the drug product should not be used. 
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9) When to seek medical attention- Statements which advise the consumer to consult 
with a physician after a certain period of time or product use, or if condition worsens, 
are usually included in the warning or direction sections of the label. 
10) Manufacturer name and address- This information is useful for consumers or retailers 
to inquire or relate to the manufacturers any feedback, problems, questions, comments, 
or procedures for returning the product. It is common practice for the manufacturers to 
provide a toll free phone number for quick access. 
11) Expiration and batch code- The expiration date should be i_n print which remains 
distinguishable over time for the determination of.when t~e product should no longer be 
used. The batch code is necessary for recall purposes. 
13) Label "flags" -Manufacturers should flag the labels of all products when "significant 
changes" are made in the product or the label information. The flags should be placed in 
a obvious place on the front of the package or container with conspicuous letter size. 
These changes may include: change or addition in claim (indication), modification of 
dosage level, change in ingredients, new warnings, or any other new information added 
to the label. These are some examples which are used. 
" See New Label" 
" See label for new ingredients" 
"New label information" 
All of this information, according to the law, must be "prominently placed" with "such 
conspicuousness", and in terms to render it to be easily read and understood when 
purchased and used under customary conditions.(7,8) 
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The Fair Packaging and Labeling Act was enacted in 1966 to provide clear and 
accurate information on the package label with regard to the quantity of the product 
contained in the package. This allows consumers to make simple value comparisons 
between products. (7) As a result of this Act, guidelines for uniform package sizes and 
quantities for four classification of OTC products, were developed by the 
Nonprescription Drug Manufacturers Association, at the request of the Department of 
Commerce. These OTC product categories included: liquid mouthwashes, solid dosage 
form headache remedies, solid dosage form cold remedies, and liquid cold 
preparations. (7) 
The 1992 amendment to the Fair Packaging and Labeling Act mandated the 
content quantity labeling for any consumer commodity to be in English units and the 
metric system. This took effect as of February 14,1994. ~efore manufacturers are 
subject to this requirement, the FDA must implement regulations.(?) 
C. Recent developments in OTC labeling 
During the initial switch process, the labeling guidelines were rigid. 
Manufacturers would propose labeling within their applications for switch, but the 
labeling which was approved and eventually placed on their OTC product was that 
developed by the FDA and NDMA. This practice has been gradually changing since the 
FDA has adopted more flexible policies which allow the manufacturer to apply their own 
labeling, once it is approved by the FDA. There are guidelines established for the 
manufacturer to follow but this is on a voluntary basis. Most of the manufacturers 
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willingly comply to these guidelines, thus creating a fairly uniform labeling system in the 
OTC market. 
In 1986, the FDA imposed a flexibility policy on the label indication section of 
OTCs marketed under an OTC Drug Monograph. This rule allows two additional 
alternatives for identifying the use of the product other than "Indications." Other 
acceptable terminology includes "FD A Approved Uses",· or "Product benefits." 
Recently, the FDA has proposed to extend the application of the flexibility rule to 
include OTCs marketed under an approved New Drug Application and Abbreviated New 
Drug Application.(3) 
More evidence is surfacing pointing to the need to provide additional information 
on OTC labels which will warrant safe use, one area being potential drug interactions 
which may occur. In August 1993, the FDA announced that some new warning 
statements will be required for antacids, laxatives, anti-diarrheals, anti-emetics, and sleep 
aids.(9) These statements will inform the consumer of some newly acknowledged 
adverse effects, and will list certain drugs which should ~ot be taken in conjunction with 
the OTC product. 
For antacids which contain aluminum, the current warning advises the consumer 
not to use the antacid while taking tetracycline, an antibiotic prescription drug. Scientific 
evidence has shown that calcium-magnesium containing antacids can also interact with 
prescription drugs as well. Therefore, the new warning statement should read "Antacids 
may interact with certain prescription drugs. If you are currently taking a prescription 
65 
( 
drug, do not take this product without checking with your physician or other health 
professional. "(9) 
In the case oflaxative and anti-diarrheal products which contain water-soluble 
gums as active ingredients, a new warning will appear as follows. "Taking this product 
without adequate fluid may cause it to swell and block your throat or esophagus and may 
cause choking. Do not take this product if you experience chest pain, vomiting, or 
difficulty in swallowing or breathing after taking this product, seek immediate medical 
attention."(9) It has been reported to the FDA that between 1970 and 1992, 
approximately 199 cases of esophageal obstruction and eight cases of asphyxia have 
been associated with concurrent use of laxative and weight control (banned from market 
in 1992) products containing water soluble gums.(9) 
Current labeling for sleep aids and anti-emetics, which contain antihistamines as 
active ingredients, warn consumers with asthma not to use the product without 
supervision of physician. The new proposed warning " Do not take this product, unless 
directed by a doctor, if you have breathing problems such as emphysema or chronic 
bronchitis, or if you have glaucoma or difficulty in urination due to the enlargement of 
the prostate gland" will replace the current waming.(9) The FDA advisory committee 
submits that the warning referring to adverse interaction~ with asthma therapy is not 
scientifically supported, and therefore it has been eliminated from the waming.(9) This 
change has affected the labeling of many OTC products which contain antihistamines. 
All information on a label, no matter how important it may be, is relatively 
useless if it cannot be easily read. Consumer groups and state governments have been 
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urging the drug industry to improve the clarity and readability of label information. A 
special task force from the Nonprescription Drug Manuf~cturers Association (NDMA) 
devised voluntary specifications for drug manufacturers to follow in order to enhance the 
readability of their package labels.(7,8) 
Readability refers to the ease, speed, and accuracy with which information can be 
read.(7) It is based upon factors such as individual comprehension, and technical or 
medical factors which the drug industry may or may not be able to control.(7) 
Comprehension is defined as the capacity for understanding fully. It is facilitated 
by the selection of simple words and phrases which can be understood by people of 
average intelligence. Comprehension by the patient depends on how information is 
presented. Problems in labeling lie in part with the FDA since it is responsible for 
developing the language used and/or approving the language proposed by the 
manufacturer. 
The technical or medical factors mentioned involve consumer variables which the 
industry or FDA cannot control such as the lighting or the atmosphere used when 
consumers read labels, age or disease- related visual impairment, or the use, or lack of 
use, of appropriate visual accessories (glasses, contact lenses). The technical factors 
which can be controlled pertain to the design of the package. These factors embody the 
layout of the package with respect to the use of small paragraphs or sections, the 
typeface which may be altered with using highlights or boldness for distinguishing 
sections or important phrases, the color of the label and ~hat of the print on the label, and 
finally, attention getters such as bullets, symbols, or boxing. (7)Some examples of these 
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variations (except color) are displayed. These are actual labels which exist on products in 
the OTC market today. Also for comparison, are photocopies of some proprietary 
packages which no longer exist in the market. 
It can be seen from the guidelines discussed, the new developments in labeling, 
and the examples of labels shown that significant advanc~ment has been made in the base 
of OTC drug information currently available for OTC package labeling. Additionally, 
the label format has been revised to improve readability of this essential information. 
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Figure 1 
MICAJAH''S Medicated ·wafers 
69 
( 
Figure 2 
Dr. SCHENCK' S Mandrake Pills 
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Figure 3 
,, 
DR MORSE' 'S Indian Root Pills 
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Figure 4 
.-· - . . 
DR. J. PETTIT' S American Eye Salve 
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( Figure 5 
PETIIT'S CANKER ·BALSAM ~~ -
For Nursing Sore Mouth, Calomel Sore Mo~th. · f ~~ 
Irritation· of the Mucous Membrane of the Mouth, 
Canker Sores and Frostbite. 
DR~ .'"PETTIT'S PILE SALVE 
Bri0gs' · Quick : Relief froin the 
Discomfort and Pain ·of Piles 
·: . · · DIRECTIONS. 
· Thoroughly cleanse the parts affecj;ed 
with Caatile Soap ·and water, .after 
·which 'apply a small quantity of .the 
Salve ·night and morning, as the case 
·may requfre. Protrudin_g piles shonld 
· be pushed· baclc. Do not" stop its· use; 
but continue if relief oi the discom-
fort seems apparent. 
R£Q. U . 9 . PAT. OFF. 
Available in Tin Boxes and in Larg~ Collap1ible .. Tin T;,_~ea 
· THE INGREDIENTS ARE THE SAME IN nJBE AND BOX 
' . 
CAUTION-Be sure to obtain 
DR. PE'ITIT'S PILE SALVE. 
The genuine baa the "tnde-
marlc" on eacli box and · tube, . 
which ia registered in the patent 
otllce at Waahington, D. C~ and . 
to counterf~it ia a felony. 
Sec 
tbal tho 
Sicnature 
PETITI'S AMERICAN EYE SALVE - .Tm box, 30c : Tube, 50c 
~ElTIT'S PILE SALVE. - - - - - Tm box, 30c Tube, 50c 
PElTIT'S EYE .WATER · ~ · - Bottle, 30c 
PETTIT'S CANKER BALSAM - -
BUTrERMILK CREAM (HOWARD'S) Tubes, 75c 
HOWARD'S BUlTERMILK CREAM SOAP-
Bottle, 30c 
Jan, $1.00 
· Per Cake - - _. - · • - · Price Twenty-five centa 
· Box of ·3 Cakes · - ·: - - - - - · Price Se-Yenty-&..e ceata 
,Manufactured by '""'. , 
HOWARD BROS. CHEMICAL CO., BUFFALO, N. Y. 
Package insert from DR PETTIT' S PILE SAL VE 
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Figure 6 
Multi~ 
lllDICATIOll: Tiie COUGH IUl'l'llUSAMT (dulro· 
-......1 lempcltarly ...... COUQll ... lo ... 
comrnon aild. TM DECOllGESTAllT (psNloepllodrinl 
lempomily relieves slufty - Ind sinus congestion 
due lo ... common cokl. The non-&SjJirin PAIN RWEVEIV 
FmR REDUCEJI (~l lemponrily l<fiMs 
minot SO<t llwool pain, hudoche. IM<. ind body Kh<s 
due lo Ille common cdd Of ... The EXPECl'OIWIT 
(gulilenesinl llefps loosen phlegm (mucus) lo dllin 
b<onchQI lubes Ind moke coughs "'°" produclr... 
DIRECTIONS: AdtMs Ind cNidren 12 )<'IS ol oge 1nd 
.,..., 2 liquid caps Mry 4 hours, no110 exceed I liquid 
caps In 24 lloun. Nol recommended lo< cllildren under 
12yeiisologe. 
fJCH UQUIO CAI' CONTAIN$:~ 250 "'9· ~ d!l!romelhorpr..n hydrobronude 10 mg. 9u.lttenesm 
"" 1?0 mo. Ind pseudoeiJ/ledlone llydroc_hloode JO mo ~ A :;a con1.,ns D&C Yellow No. 10. ro~c Red No. 40. ,, gelltin. gt,ufin. polyet1lytene atla>I. povidone_ propylene , glycol. purified w.ier. Ind SC<f>Col. WAIWNGS: Do no1 exceed recorMlended ~ bea14e 
.. ligllel dose$ - · clininess. Of .....,,... 
1NY oa:ur. Do nol lalre l1is product lor "'°" INn 1 dlys. 
A ~ COUQll moy be • sign ol 1 serious c:andilion. n 
couoh « Olher sympioms per>isl lor "'°" INn 1 days. 
lencl lo recu1, Of .,. ~ by mh. penislenl 
helWr:he, IMr INI llsls lor more INn 3 CSJys. or I new 
S)'ll1Jloms oa:ur. aJflSIA • plly5ician. Do nol '* ... 
piodud tor~ ordvonic couoh 5"dl .. oa:urs 
with smoluno ........ dvonic bronchilis. emc>hysl!IN. Of 
- couoli Is ~ by . pllilQnl (-:.., .. dinQed by. pllysiciao. "T:: 1hnNi" ii 
~lor-""2dlys,il~Of 
consul!•~=~~=' you r..ve high blood pressure, helrt disuse, clilbetes, 1hyroid disuse. or difficutty In urinllion due lo 
enllrgemenl of Ille prosl•le gllnd tlUIJI undef Ille 
ldW:e Ind ~ ol a physidin. ~ with d<llQ, ~ you ¥t prtgninl Of nursing I baby. 5'6 Ille~ ol 
• .....,, professioNI belO<t using lhis producl. 
Drlf llMndiN P11cHtl01: 0o nol llke !his product I 
you .,, praenlly llkinQ • prtseription ~
Of lnlide!l<<SS>nl d1119 conlJinino • monounont oxldose 
inhibil« errcepl under Ille ldvice •nd supeMsion ol • 
~S ANO All DRUGS OUT OF THE REACH OF 
CHILDREN. In use of icadenlll OYl!ldoso. seett pro· 
lessionll 1Ssisllnce « a>nlld • Poison Conlrol Center 
immedi•lely. Prompt medic•I 1llen110f1 is crijaf lo< 
aduhs H well is for cMdren Mn I you do nol nolitt 
iny siQns 0< symptoms. 
Slort 11 IS" lo 2S 'C (59" lo 17"f) In a dly plu Ind prflled 
ln>mliglt 
\l&, m:Q. •• ~ 0081-0677-13 4 
Current cold product, name not disclosed, shows one format of"section" labeling. 
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Figure 7 
eftfffu, Ifft ,,., ....... ti IHltlHCI et cttllttct I,....,. 
::::~~:~-:1·.~~=.'.:~-=:. 
...... a .. , ..... .,~ ........ , .. , ,,,.. 
~i:.::1:::t ::,:!'~1.: :.:.:';,::.~ Nricl tf I Me• 
DfllUG IMTEflACflON rft(CAUTION: Oo noc use thrt; ptOdud 
If you Mt tat~ I Off:Knpbon dnlQ tonUtl'MnQ ' rnonoMW'll 
~uc1'~:::""tn!oc~l:c,n:,.~,~T"":'~ ~~ = =-~~ ~e:::::h":::r=e::: *"' .. IA""O :t-Js Pfoduct 
ACn'/f ltlGAfDtUfTS: ns mo~·· 100 mo 
~.>Omcl'K-ineHClondlOmo ,, 
0.--HBtPtfuplet, 
IMACllVf IMGA!OlfMIS: JO&C .... II Ult. fO&C Y-
:~~::'1t~~~~td1. 
 Glr<ol. Poiy<otb.,t IO. P-. S.O.... 
fillft!UmCSodfVMStu•wtrum.a1111. sc1'°'· 
St0te it 1oom lt"'OtflhHI 
N 
3 4 
Current cold product, name not disclosed, shows another format utilized. 
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( For switch medicines, more information may be needed to assist the consumer 
not only in recognizing symptoms treatable by the OTC drug product, but also 
identifying symptoms which are not associated with the particular treatment at hand. 
With these medicines in particular, referring the consumer to seek professional advice is 
imperative. This warning should appear in more than one section of the label. 
It is common for manufacturers to include a statement on package labels of 
switch medicines informing consumers that the active ingredient was previously available 
only as prescription. Manufacturers have been creative in stating this in several ways: 
Original Prescription Strerzgth 
Now Available Without Prescription 
Now ... In Non-Prescription Strength 
Maximum Strength available without prescription 
Strongest Formula Available without prescription 
Formerly Prescription Strength 
Prescription Strength without a prescription 
Full Prescription Strength 
No Prescription Needed 
Referencing prescription status on the label alters consumers' perception of the 
product as one being very powerful, and therefore more effective. Some consumers may 
hesitate to use the product and seek professional advice, which is always advisable. For 
others, the fact that the product is now available to them without a prescription is 
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attractive, and therefore the product has the potential of being overused or misused. 
For these reasons, labeling is even more important on switch products to provide 
information that reassures consumers about the products' safety and effectiveness, and 
emphasizes the importance of reading the label thoroughly. This is an issue which must 
be considered by the FDA as more switch products enter the OTC market. 
ill. Advertising 
A. The Federal Trade Commission 
In March of 1914, five individuals were appointed to a commission with the 
objective of investigating corporations for violations of antitrust laws and the use of 
unfair methods of competition in commerce within the United States or between the U.S. 
and foreign countries. (2,6) The federal act which empowered the commission to 
perform these duties was the Clayton Act. (2,6) The sec?nd legislation that addressed 
the commission's authority and responsibilities was the Federal Trade Commission Bill, 
proposed by Congressman Clayton, which was passed on Sept. 26, 1914 and renamed 
the Federal Trade Commission Act. This Act defined the commission's powers and new 
identity as Federal Trade Commission (FTC). (2,6) Additional members were 
transferred to the FTC from the Bureau of Corporations.(2,6) The scope and extent of 
the FTC' s responsibilities has changed over time. Coinciding with the implementation of 
new regulations of drugs in 1938, the FTC began its involvement with OTC drug 
advertising. Today, the FTC is charged with extensive and diverse activities, maintaining 
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the objective to safeguard the public and businesses from unfair or deceptive practices in 
competition. 
B. Review of Advertising Regulations 
As defined in the Federal Trade Commission Act, "advertisement" shall mean 
any written or verbal statement, illustration or depiction, other than a label or in the 
labeling, which is designed to promote the sale of a product, whether the same appears in 
a television, radio broadcast, newspaper, magazine, leaflet, circular, book insert, catalog, 
sales promotional material, billboard, or in any display intended for use at the point of 
purchase of the product.(11, 12, 13) 
The first legislation imposed in the United States towards the regulation of 
advertising was the "Printers' Ink" statute. This statute was drafted in 1911 by the 
Printers' Ink Publishing Co., Inc., and adopted by most states for the purpose of 
regulating dishonest and/or misleading advertising. The statute imposed criminal 
penalties for violations, and prohibited untrue, deceptive, or misleading advertising of 
products or services.(2) 
Some examples of earlier and current advertisements are included for comparison 
purposes . It can be seen from the examples why regulators were concerned about the 
messages being sent to the consumers regarding product claims. 
• antacids- alleviate complaints resulting from nervous or emotional ·sickness, 
consumption of alcoholic beverages, morning sickness 
• sleep aids-promote natural or normal sleep 
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e.g."Compoz"-Family Circle offered in bold type- "we will give you 50 cents to 
try compoz today. The ad read 
"Compoz is a simple medication formulated for those occasional nights when simple nervous 
tension keeps you tossing and turning, unable to fall asleep. Compoz helps you relax that simple nervous 
tension, eases that minor temporary tenseness. Compoz helps you fall asleep more naturally, more 
easily. And unlike sleeping tablets that leave you with a drugged feeling the morning after, Compoz lets 
you wake up feeling fresh as you can be. But for those occasional nights when simple nervous tension 
keeps you awake, take Compoz with confidence." 
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Figure 8 
**Vicks-Va-Tro-Nol, Ad reads: Put 3-purpose Va-tro-nol up each nostril .. (1) It 
shrinks swollen membranes; .. (2) Soothes irritation; .. (3) Helps flush out nasal 
passages, clearing, clogging mucus.(no longer marketed) 
-appeared in New York Times Jan. 3, 1941 
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Figure 9 
FOR QUICK RELIEF FROM 
HEADACHES 
IO~ ANO 25~ 
BCP Powders (still marketed) 
appeared in LIFE magazine, 194 7 
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Figure 10 
I. Ting stops the itch of 
athlete's foot. 
2. Ting kills the fungus of 
athlete's foot. 
3". Ting kills the bacteria 
of athlete's foot. 
4. Ting checks 
the recurrence of 
athlete's foot. 
(And Ting does all this in a unique way.) 
~:."'0:.-=".~·.:~ ~ : 
Ting goes on as an antiScptic 
medicated cream that geis to the cause 
of athlete's foot. Then, in a few 
minutes, Ting turns into an antiseptic 
powder that cools and dries the feet, 
reduces friction between toes and 
helps new sic.in to grow. A cream · 
that turns into a powder; now you see 
why Ting is unique. Also available : 
Ting Antiseptic Medicated Powder 
to help prevent re-infection. 
\Va•t proof of Tine'• dl"ectin:nc:sa? 
~ Jot f« sample to : 
Tinc-Dept.VE-J, Phannacr.aft Laboratories. 
Cr:anburv. New Jencv 
*Ting ointment(not marketed) 
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The advertising of Over-the-Counter( OTC) medicines was not specifically 
addressed until the labeling standards of these products were mentioned in the drug 
regulations. In 1912, the Sherley Amendment to the 1906 Pure Food and Drug Act, was 
an attempt by regulators to stop deceptive labeling and promoting.( 4) The challenge 
facing the courts was in proving that a promotional claim was false, or that a claim was 
set forth deliberately with the intent to deceive, which accounted for the existence of 
erratic advertising. (2, 4) 
The Wheeler-Lea Amendment to the FTC Act in 1938, made it possible for 
regulators to exert control over the advertising of OT Cs. A contributing factor to this 
was the enactment of the Food, Drug, and Cosmetic Act of 1938 which imposed safety 
requirements on new drugs. Advertisements could no longer promote medicines in a 
manner which may lead to unsafe use of drugs.(4) 
When the advertising era peaked in the mid 1970's, a new regulation was 
imposed to monitor the material content in advertisements. It was at this time, the 
Federal Trade Commission Act was amended to prohibit advertisers, in describing the 
therapeutic benefits of their OTC products, from using language not approved by the 
FDA, for labeling as published in its final monograph( 4). This requirement would take 
effect at the time of the publication of the monograph, to avoid a lag time between the 
effective date for regulation of an OTC product and the regulation of advertising for the 
same ingredient. 
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C. The Federal Trade Commission and OTC Advertising 
As discussed earlier, the FTC was created to control and prevent persons or 
corporations from conducting business using unfair or deceptive methods of competition. 
To reiterate, the Commission carries out its functions under the Federal Trade 
Commission Act. When the Act was amended in the mid 1970s to include deceptive and 
fraudulent advertising, the FTC's new scope then included and continues to include OTC 
advertising. ( 4) The realm of activity continues to be the printed or spoken advertising 
message, and its functions extend to all national advertisers and their advertising 
agents.(11, 12, 13) The Commission's authority is not limited to preventing deceptive 
acts or practices or false advertisements. It can operate under the theory that a practice 
is unfair if it offends public policy which Congress has enacted for the protection of 
public health.(11, 12, 13) 
The FDA holds no authority over the advertising of OTC medicines, however, it 
can prohibit the sales of falsely advertised products. The FDA serves usefully as an 
advisory body for both the FTC and Federal Communications Commission(FCC). The 
FCC is a commission which allocates the times and time limits for television 
advertisements. ( 4) 
The major objectives of the FTC's advertising regulations are to encourage 
truthful advertising, prevent advertisers from employing deceptive or unfair advertising 
claims and methods, and to ensure advertisers disclose limitations and health risks.(2,4) 
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D. Nonprescription Drug Manufacturers Association (NDMA) 
In 1973, the NDMA (formerly The Proprietary Association) in conjunction with 
the National Association of Broadcasters, developed a code of guidelines for 
manufacturers to follow in creating television advertisements for OTC medicines. (7) 
These guidelines impose high standards of truthfulness and honesty, and convey the 
critical nature of the products being advertised. A summary of some of the specifications 
for advertising of OTCs is outlined below.(7 ) 
• Advertising of an OTC medicine should urge the consumer to read and follow label 
directions. 
• Advertising of an OTC medicine should not contain claims of product effectiveness 
which are not supported by clinical or other scientific evidence. 
• An advertisement of an OTC medicine should not be presented in a manner which 
suggests prevention or a cure of a serious condition which must be treated by a 
licensed practitioner. 
• An advertisement of an OTC medicine should not show dramatizations of ingestion 
of medicine unless it is informing the consumer of proper administration of the 
medicine. 
• An advertisement of an OTC medicine should.not ref.erence doctors, hospitals, or 
nurses unless such representations can be supported by independently conducted 
research. 
• An advertisement of an OTC medicine should emphasize uses, results , and 
advantages of the product advertised. Negative or unfair reflections upon competing 
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OTC products should not be presented unless they can be scientifically supported 
and presented in a manner such that consumers can perceive differences in the uses. 
• An advertisement of an OTC medicine which references scientific or consumer 
studies should present actual research performed and results interpreted honestly and 
accurately. 
E. Advertising Expenditures 
Advertising OTC drug products reaches the public through newspapers, 
television, radio, magazines, billboards, counter and floor product displays, and several 
other forms of media. The amount of dollars spent on advertising by manufacturers on 
drugs and cosmetics continues to exceed that of other categories. ( 10 ) 
Table 1 
Advertising Volume for Selected OTC Product Categories, 1972 
Category 
Dental supplies 
Headache, sleep 
Cold, cough,sinus 
Digestive, antacids 
Medicated skin 
Vitamins 
Feminine 
Laxatives 
Weight control 
Total 
1972 (millions) 
$112 .. 0 
99.5 
77.4 
45.0 
39.1 
29.9 
26.8 
16.8 
4.0 
450.5 
*Source- Product Management. "The Advertising Age." Drug Topics,(Aug. 23, 1973) 
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F. Advertising of Switch Medicines 
With a large prescription user base, there is a general familiarity of many 
prescription tradenames which are frequently used in treating common conditions such as 
allergies, stomach ulcers or excess acid, and arthritis. This is exemplified by the volume 
of sales (Table 2) for the newly switched products in the 'market today. It so happens, 
many switch products and future switches arise from these therapeutic areas. These 
drug products are considered for OTC use because consumers tend to understand and 
easily recognize symptoms from these conditions. Since these conditions occur rather 
frequently throughout the population, the associated prescription products have been 
heavily relied upon as part of the symptomatic treatments. Once approval for a switch is 
granted by the FDA, manufacturers have a definite advantage in promoting their switch 
drug, since their product's tradename and reputation is already established. 
Manufacturers take advantage of this through product advertising and package labeling. 
As an example, when Upjohn received approval for a nonprescription strength of their 
prescription product Motrin (ibuprofen), they wanted to maintain the consumers' 
recognition for the prescription tradename, therefore, the OTC version was named 
Motrin IB. If Upjohn received approval for ibuprofen to be switched under a petition 
method rather than a new drug application, they would have been able to maintain the 
identical tradename. Since the tradenames are nearly identical, Upjohn has been able to 
promote their OTC product successfully. Other manufacturers in competition with the 
same active ingredient do not have the same advantage in promoting their OTC product 
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but benefit with focusing their advertising on the availability of an OTC strength of a 
prescription product. 
For the switch product Benedryl, manufactured by Parke Davis (division of 
Warner Lambert), the tradename was allowed to remain the same because it was 
switched under the petition method and not treated as a new drug. This has contributed 
to the success and popularity of the OTC product. Advertising for this product is no 
longer focused on the switch aspect but on the usefulness in treating allergies and cough 
and cold symptoms. 
Also through advertising, manufacturers emphasize the fact that a potent but safe 
and effective prescription drug with an established reputation with doctors, pharmacists 
and the FDA is now available to consumers. Additionally, one can note the use of the 
word cure in addition to symptomatic relief which is the only approved use of many 
traditional OTC products. This trend to promote a cure places a special responsibility on 
the FTC and FDA to ensure that the advertising and labeling is not misleading. 
Consumers must be made aware of the appropriate use and limitations of a switch 
product to avoid complications in the condition being treated. The manufacturer also 
needs to stress the potency of the drug product and the need for careful monitoring of 
results so that medical intervention can be sought if necessary. 
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-Table 2 
Popularity of Switch Medicines 
Of the ten best selling OTCs, nine were switches and one was switch-related 
Product Marketer 1991 Sales Type 
($MM) 
Advil American Home Products 285 Switch 
00 Monistat 7 Johnson & Johnson 90 Switch 
'° Sudafed Burroughs Wellcome 81 Switch 
Dimetapp American Home Products 78 Switch 
Motrin IB Upjohn 74 New Proprietary 
Nuprin Bristol-Myers Squibbb 74 Switch 
Benadryl W amer-Lambert 73 Switch 
Gyne-Lotrimin Schering-Plough 63 Switch 
Actifed Burroughs-Welcome 61 Switch 
Afrin Shering-Plough 54 Switch 
Source- Sudler & Henessey, NY 1992. 
IV. Summary 
Appropriate labeling and advertising are crucial instruments that can be useful in 
educating consumers on the safe and effective use of switch products. The agencies and 
systems are in place to bring forth smooth transitions of prescription products to OTC 
status. However, these agencies must be vigilant in monitoring the potential for 
manufacturers to promote their products in false or misleading ways in order to gain a 
market edge. Afterall, success in the consumer market goes to whomever has the most 
persuasive labeling and advertising. 
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MANUSCRIPT IV 
CURRENT PERCEPTIONS ABOUT OVER THE COUNTER 
MEDICINE LABELING AND ADVERTISING 
92 
( 
I. Introduction 
Current Perceptions About Over-the-Counter 
Medicine Labeling and Advertising 
Several prescription medicines are currently being switched, or considered for 
switch to the over-the-counter (OTC) market for direct availability to consumers. As a 
result of this Rx-to-OTC switch trend, and in light of health care reform to reduce the cost 
of health services, the roles of heath care professionals are changing. :Physicians have long 
assumed the role as the primary care giver with the consumer as the care recipient. 
Today, there is an additional level of health care providers. Nurses, nurse practitioners 
and physician assistants provide direct patient care for many health problems. In some 
states these professionals are authorized to prescribe drugs applicable to their scope of 
training. Additionally, in Florida and California, pharmacists are authorized to prescribe a 
limited number of drugs to consumers without any inteniention of physicians. Pharmacists 
are the most approachable health care professional to consumers and their accessibility 
complements the trend toward self-medication. They have served and continue to serve as 
the mediator between physicians and consumers, supplying both with OTC and 
prescription drug information, monitoring drug interactions and patient compliance. These 
particular responsibilities will persist for pharmacists but with the ongoing trend of 
switching prescription drugs to OTC, more time and effort will be directed toward 
counseling patients for the appropriate use of OTC medicines. 
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Health care professionals generally recognize that the worsening economic 
situation has contributed to a reduction in doctor office visits by consumers seeking 
medical intervention. ( 4,5,8 ) Consumers are additionally seeking assistance from lower 
level providers, especially in managed care environments. They also have the option of 
visiting any retail store and selecting an OTC product. In fact, more OTC medicines are 
being used by consumers, in part as an effective and affordable alternative to an expensive 
office visit.(6,8) At the same time consumers are currently accepting more responsibility 
for their own health care. This includes recognizing symptoms of conditions previously 
diagnosed by physicians, such as yeast infections, allergies, skin conditions, and arthritic 
episodes. Consumers now routinely make the decision to self-medicate these problems, 
and determine when or if a physician, or other health care professional, needs to be 
consulted. 
Pharmacists, physicians, nurses, and other health care professionals will no doubt 
continue to be vital components in the health care delivery system, although, as self-care 
increases, their role as a primary provider is changing to one of an educator. The 
information they can provide to consumers is essential to promote the safe, appropriate, 
and responsible use of the newly available OTC medicines. For this reason they must be 
knowledgeable about these products. In addition to the input from health professionals, 
the consumer can also rely on two other methods for obtaining information about OTC 
products labeling and OTC advertising. It is essential, therefore, that consumers receive 
accurate, clear, and complete information from these venues if the products are to be used 
properly. 
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The fact that American consumers have become increasingly health conscious has 
resulted in their assuming greater responsibility for their health care. This "take-charge" 
attitude has had a significant impact on the use of OTC medicines in self treatment. With 
the Rx-to-OTC switch trend in place, consumers are experiencing constant changes in 
their options for various drug treatments. It is well established that consumers are no 
longer running to physicians with minor ailments or even recurring conditions which were 
previously diagnosed by physicians.(5,6) In addition to seeing health care professionals, 
they can visit any retail store and choose from an a wide selection of effective OTC 
products, read package labeling for instructions, and begin treatment almost immediately. 
The first phase of this study was designed to assess consumers' attitudes and 
perceptions about prescription medicines being switched for OTC use, their patterns of 
use for OTC medicines, and the factors that influence their decision in selecting a product. 
One important issue throughout this part of the study was to gain insight on consumer 
perceptions of OTC package labeling in terms of readability and understandability since 
the information on the product is crucial to appropriate use. Understa~dability was 
evaluated through consumers' interpretation of terminology found on current package 
labels. The responses were then compared across consumer variables such as age, 
gender, education, income, and language skills to see if differences existed across the 
variables. 
Phase II of this study examined pharmacists' and physicians' perceptions of current 
labeling and advertising with respect to the content, readability, and comprehensibility of 
the information provided. Another part of the study was to assess pharmacists' and 
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physicians' awareness of the trend of switching safe established prescription medicines to 
OTC status for the improvement of patient self-medication. It was also of interest to 
identify patient characteristics that these health professionals believed contributed to safe 
and proper use. 
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II. Methods 
A. Phase I 
Since Phase I was an exploratory study designed to evaluate certain consumer 
variables for their effect on the readability and understandability, the distribution of the 
surveys was based upon two considerations. The first goal was to target specific 
populations that were expected to provide useful data on the use of OTC products. The 
second goal was to obtain responses from consumers in various demographic categories. 
The sample size and distribution were designed to meet the cost limitations allowed for the 
study. 
To meet the first goal, a large chain drugstore was selected for sample collection 
since it is well established that consumers prefer purchasing OTC medicines in drugstores 
compared to supermarkets or other retail establishments. This prefere.nce has been 
verified through sales analyses and consumer polls. In 1992, Towne-Oller & Associates 
analyzed on the sales of OTCs in drugstores and foodstores and found that drugstore sales 
accounted for $6.2 billion while foodstores showed $5.3 billion.(12 ) Consumer polls 
have revealed that consumers prefer drugstores in part because of the accessibility of 
pharmacists for OTC information. (3) 
Since the goal was to target a sample of consumers who are likely to use OTC 
medicines and/or seek assistance from pharmacists, it was decided to make the surveys 
accessible through the pharmacy service end of the drugstore only. The distribution 
involved placing the surveys with a clipboard on pharmacy counters. A sealed box, labeled 
URI RESEARCH. was also placed on the counter for the consumers to place their 
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completed surveys. A cover letter attached to a three-page survey introduced the research 
focus, the purpose of the project, and assured confidentiality to encourage completion. 
The survey requested the following demographic data from consumers: age, level of 
annual income, last school completed, gender, and native language. While cost and time 
limitations precluded drawing a statistically random sample, this blend of urban and rural 
stores across the states was used to approximate a balance blend of respondents. 
The second consideration for targeting the sample population was a demographic 
distribution to represent the urban, suburban, and rural geographic areas in the state of 
Rhode Island. The 1990 census data aided in the selection of eight cities and towns from 
· the total 39 comprising the state. These eight locations were primarily selected for their 
distribution of educational level, yearly income, and language skills. 
B. Phase II 
Both pharmacists and physicians were solicited in this study because their direct 
patient interaction should result in an awareness of consumer perceptions of health and of 
their self- medication practices. In general, the size of the sample was determined by the 
cost of conducting the study, and by the desire to limit the scope to in-state practitioners. 
A random sample from the physician and pharmacist populations was selected from the 
Rhode Island Department of Health's listing of registrants. The list of registered 
physicians contained 3,050 names and addresses . . Every fifth physician name was selected 
for the mail distribution if it included a Rhode Island address and did not identify 
specialties including pathology or radiology. If either were the case, the next name in line 
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was selected. The list of registered pharmacists contained 1,243 names. To obtain a 
sufficient sample size comparable to the physician sample, every other name was selected 
for the mail distribution provided it was a Rhode Island address. 
The three page survey for health professionals did not request demographic 
information and practice characteristics for physicians or pharmacists. Rather, the 
questions were designed to allow the respondents to identify iftheir scope of practice was 
such that it was inappropriate to answer a question. Regardless of their scope of practice, 
it was expected to be useful to have their views as health care professionals, and as 
consumers, about the changing health care trends and package labeling. The distribution 
involved a one-time mailing without any form of announcement, reminder, or second 
mailing. Confidentiality was assured to encourage completion of the survey. 
The data was analyzed using SAS software program and statistical significance 
was determined by the Chi Square test statistic with a probability (p) value less than 0.05. 
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ID. Results and Discussion 
Several national studies have been conducted to find out about the practices of 
American consumers with respect to self-treatable health problems. In these studies, much 
emphasis was placed on how and to what extent consumers use OTC medicines and 
whether the package labels are read and/or understood. These studies will be frequently 
referenced in the comparison of national data to the Rhode Island regional data. The 
Rhode Island survey obtained similar information to these studies, however, it placed more 
focus on consumer's ability to understand the terminology on package labels. 
Additionally, the survey inquired about consumer views on the trend of switching drugs 
from prescription status to OTC status. The Rhode Island study also surveyed 
pharmacists and physicians, not only for their knowledge of label and advertising, but also 
their perceptions of consumer capabilities of understanding OTC labels and advertising. 
The locations for the consumer survey are listed in Table 1 which also shows the 
distribution, sample size and response rates. The consumer respondent demographics are 
presented in Table 2. A total of 164 surveys were used in the data analysis. 
Valid responses were received from 154 (25.4%) of the 606 physicians surveyed, 
and these were used in the analysis. Four responses were eliminated because of retirement 
status. For pharmacists, 202 (32.7 %) ofthe 617 surveyed provided valid responses used 
in the analysis. Three of the responses were eliminated because of retirement status. The 
sample sizes and response rates for phase II are illustrated in Table 3. 
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Table 1 
SAMPLE DISTRIBUTION, SIZE AND RESPONSE RATES, CONSUMERS 
Category of Data Urban Suburban 
Original Sample 200 300 
Final Sample* 40 84 
Response Rates(%) 20% 28% 
* Includes ~ompleted surveys returned. 
Urban includes the cities of Providence and Pawtucket. 
Suburban includes North Kingstown, Wakefield, and Westerly. 
Rural includes Tiverton and Slatersville. 
I 
The net response rate for all consumers= 27.% 
.......... 
Rural 
100 
40 
40% 
Table 2 
CONSUMER RESPONDENT DEMOGRAPHICS 
Income 
Under $10,000 29 18% 
$10,000 - $19,000 29 18% 
$20,000 - $29,000 33 20% 
$30,000 - $44,000 42 26% 
$45,000 - $59,000 17 11% 
$60,000+ 12 7% 
Education 
Less than High School 4 2% 
High School Graduate 63 39% 
Trade School 13 8% 
4 Year College 50 31% 
More than 4 Year College 25 15% 
None of the Above 8 5% 
Gender 
Female 110 67% 
Male 54 33% 
A e 
19 - 24 20 12% 
25 - 34 49 30% 
35 - 44 49 30% 
45 - 59 13 8% 
60+ 33 20% 
-
Native Language 
English 144 88% 
Spanish 18 11% 
Portugese 2 1% 
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Table 3 
SAMPLE SIZE AND RESPONSE RA TES FOR PHYSICIAN AND 
PHARMACIST POPULATIONS 
Category of Data 
Original Sample 
Final sample* 
Valid Responses 
Response Rate(%) 
Physicians 
610 
606 
154 
25.4% 
Pharmacists 
620 
617 
202 
32.7% 
* Excludes survey respondents who identified themselves as retired and felt 
unable to respond accurately. 
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Phase I - Consumer Survey 
The consumer survey was divided into three sections. The first section was 
designed to find out who uses OTC products and the frequency of use. This section asked 
consumers for demographic information including their age range, last level of school 
completed, gender, native language, and range of annual income. The second section 
identified the factors which are used in the selection of an OTC product. These factors 
included where they were purchased, whether a professional was consulted, and if 
television advertising influenced their decision. The third section asked consumers for 
their opinion on the readability and understandability of OTC package labels. The final 
section asked about consumer perceptions on switching clrugs from prescription to OTC 
status. The following discussion focuses on the points identified above. 
Who uses OTC medicines? 
The Rhode Island study found that 97 percent of consumers rely to some degree 
on OTC medicines. This number was expected since the sample contained drug-store 
patrons. Of this group, 31 percent say they always use OT Cs. This trend seems to be 
consistent with the results reported by Princeton Survey,(10) where 88 percent of adult 
consumers said they use OTCs, with 19 percent saying they use them often. 
The 1992 study conducted by the Princeton Survey Research Associates, for the 
Council on Family Health, published in Prevention Magazine, "Using Medicines Safely'', 
surveyed American consumers for their use and attitudes regarding OTC and prescription 
medicines.(10) Specifically, the incidence of OTC use, and the practice of reading and 
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understanding labels, were of particular interest. The study was conducted by 
interviewing 1,250 consumers, randomly selected, by telephone during November and 
December of 1992. 
The Rhode Island study may be biased in these results because of the limited study 
population. Table 4 displays the breakdown relating the frequency of use. These results 
reflect the changing health care environment in which consumers are interested in 
assuming responsibility for their general well being. OTC medicines are viewed as a useful 
therapeutic alternative to costly, time-consuming physician intervention. Today, a 
significant number of people rely on OTCs or home remedies to treat minor ailments. 
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How often? 
Always 
Sometimes 
Rarely 
Never 
Table 4 
WHO USES OTCS? 
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% Total Respondents (N) 
. . . 
31% (51) 
57% (93) 
9% (1°5) 
3% (5) 
( 
The national trend of women using more OTC medicines than men is not observed 
in the findings in this survey. Ninety-one percent of women said they use OTC medicines. 
Of these women, 33 percent responded using OTCs always, 58 percent said sometimes 
and only one respondent said never. In the case of men, 82 percent responded favorably 
to the use of OTCs. Of this group, 28 percent said always, while 54 percent said they use 
OT Cs sometimes. Only 7 percent of men compared to 1 percent of women said they 
never use OTCs. There is no significant difference observed between women and men in 
using OTCs. Since more women responded to the Rhode Island survey, this may account 
for the slight increase in the observed percentages and result in bias. Table 5 shows the 
results broken down by gender. The Princeton survey reported women(62%) were more 
likely than men to use OTCs compared to men(47%). (10) Table 5 also shows results for 
this study. 
In this country, women have traditionally taken care of such domestic duties as 
household shopping which included buying groceries and health and beauty aids. 
Although more women are finding themselves in the paid work force, in most cases, they 
maintain the same shopping practices. (8) Among their traditional responsibilities is caring 
for children. When children are sick , women are usually the ones to take them to the 
doctors, and then to the pharmacy for prescription or OTC medicines that the doctor 
prescribed. Although these roles have been gradually changing, the gender factor may 
account for the availability of more data from women about OTC medicine use. The 
Rhode Island study obtained completed surveys from 110 females compared to 54 males. 
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Table 5 
WHO USES OTCS? GENDER COMPARISON 
How often? 
Always 
Sometimes 
Rarely 
Never 
Often 
On occasion 
%Male (N) 
28% (15) 
54% (29) 
11% (6) 
7% (4) 
Princeton Survey(lO) 
15% 
32% 
108 
%Female (N) 
33% 
58% 
8% 
<1% 
23% 
39% 
(29) 
(64) 
(9) 
(1) 
( 
( 
Other demographic characteristics assessed for their potential influence in the use 
of OTC medicines were income and education. See tables 6 and 7 for the results. It 
appears as though both of these factors affect the consumer reliance on OTCs. For the 
respondents with income in the range of$10,000 and $19,000, 76 percent said they used 
OTC medicines compared to the five other income levels where 88 to 93% of these 
respondents use them. The highest reported use (93%) was by respondents with an 
income in the range of $30,000 to $44,000. Since most of the respondents (42) fell into 
this income category, the results may be biased. Consistent with national data, there are no 
statistically significant differences in the use of OTCs with respect to income. 
Heller Research Group in their study" Self-Medication in the'90s: Practices and 
Perceptions" reported 38 percent of adults earning $20,000 or more reported frequent us 
ofOTCs compared to 33 percent of adults earning $20,000 or less. Overall, there were no 
major differences observed in the use ofOTCs with respect to income. The Heller 
study's national sample included 1,500 American consumers who were interviewed by 
monitored telephone interviews and self-completion questionnaires. These consumers 
were asked about their practices with OTCs and self-medication and their overall attitudes 
regarding OTC drugs and moreover, their feelings about the Rx-to OTC switch trend. 
With regard to education and the use of OTCs, there was a significant difference 
for those respondents with an education less than high school. Fifty percent of them 
reported using OTCs. For those respondents with high sehool education and above, the 
reported use of OTCs ranged from 84 to 94%. The maximum use (94%) was reported by 
respondents who completed 4 years of college. These results are unexpected since 
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consumers in the lower income and less education groups would be expected to have the 
most reliance on OTCs as an alternative to medical intervention for health care services. 
The Heller study showed similar results. For adults with high school education or less, 35 
of them were inclined to use OTCs where 38 percent of adults with some college or more 
would use OTCs.(6) 
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Table 6 
WHO USES OTCS? COMPARISON OF INCOME 
. 
Level of Income %Total (N) % Yes(N) % No (N) 
< $10,000 18% (29) 89% (26) 3% (1) 
$10-$19,000 18% (29) 76% (22) 10% (3) 
$20-$29' 000 20% (33) 87% (29) 3 % (1) 
$3 0-$44' 000 26% (42) 92% (39) 
$45-$59,000 11% (17) 88% (15) 
> $60,000 7%(12) 92% (11) 
- Yes includes the responses always and sometimes. It does not include rarely. 
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Table 7 
WHO USES OTCS? COMPARISON OF EDUCATION 
. 
Education level % Total (N) % Yes (N) % No (N) 
Less than High School 2% (4) 50% (50) 25% (1) 
High School equiv. 39% (63) 86% (54) 5% (3) 
Trade School 8% (13) 92% (12) 
4 Year College 31% (50) 94% (47) 
> 4 Year College 15% (25) 84% (21) 
None of the above 5% (8) 87% (7) 13% (1) 
-Yes include always and sometimes. It does not include rarely. 
( 
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The age factor was also evaluated by the Rhode island survey. Table 8 displays the 
results for each age range. For the ages between 19-44, 30 percent of the respondents 
said they always used OT Cs, while an average of 5 8 percent of the respondents said they 
sometimes use OTCs . The 15 % of the 45-59 age group said they always use OTCs and 
69% of them sometimes use OTCs. Thirty-nine percent of the 60 and over respondents 
said they always use OTCs and 39% sometimes use OTCs. This last finding is unexpected 
since the Heller study showed for the 65+ group, only 28% relied on OTCs compared to 
the 38% average for the other age groups. One would expect that elderly would avoid 
using as many OTCs as younger people since they are usually taking other prescription 
medicines or have conditions in which OTCs are contraiqdicated with. On the other hand, 
with the lessened availability of medical insurance for doctor office visits and prescription 
medicines, the elderly may be more inclined to rely on OTC medicines as a cost effective 
alternative. 
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Age range 
19-24 
25-34 
35-44 
45-59 
60+ 
Table 8 
WHO USES OTCS? COMPARISON OF AGE 
%Total (N) 
12% (20) 
30% (49) 
30% (49) 
8% (13) 
20% (33) 
%Yes (N) 
85% (17) 
90% (44) 
94% (46) 
84% {11) 
78% (26)* 
-Yes includes always and sometimes. It dose not include rarely. 
%No (N) 
4% (2) 
8% (1) 
6% (2) 
* 15 % said rarely accounting for no significant difference between age groups for 
responding favorably to the use of OTCs. 
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The last factor studied for its effect on the use of OTCs was language skills. Table 
( 
9 includes the results. Although the test group only included twenty respondents who 
identified a language other than English as their native tongue, and attempt was made to 
. 
determine iflanguage had an effect on selection. One hundred percent (N=2) of 
Portuguese individuals reported using OTCs sometimes. Spanish respondents reported 
73% (N=18) use OTCs always or sometimes and 15% never use them. Comparing 
English and non-English speaking respondents in their use of OTCs, 88 percent and 80 
percent respectively use OTCs always or sometimes. It is impossible to draw conclusive 
evidence that language affects the selection of OTC products from such a small sample. 
These data and the national statistics cited support the routine use of OTCs 
by consumers. The Heller study showed that OTC use has actually increased from 1983 
to 1992. Figure 1 shows the breakdown of what consumers do for health problems. This 
reinforces the concept that consumers are willing to find their own solution to recurring 
problems and OTCs provide an available option. 
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How often? 
Always 
Sometimes 
Rarely 
Never 
Total 
Table 9 
WHO USES OTCS? COMPARISON OF LANGUAGE 
% English (N) 
33% (47) 
56% (81) 
8% (12) 
3% (4) 
88% (144) 
% non-English (N) 
20% (4) 
60% (12) 
15% (3) 
5% (1) 
12% (20) 
Total Yes for English= 97% and non-English 95% resulting in no significant difference. 
Sample size to small to make accurate inferences about language skills. 
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What factors influence consumer selection of an OTC product? 
Questions were posed to identify not only the retail environment preferred for 
purchasing OTC medicines, but also to see what other factors may influence these 
preferences. Specifically, the survey asked the consumer which of the following was a 
significant influence in their decision to choose an OTC drug: primary care provider, 
package labels, family, friends, media, or any other mentioned source. 
The Rhode Island study showed that consumers prefer to purchase OTC medicines 
from drugstores. The results from this study may be biased since the survey was only 
accessible to consumers in the drugstore environment. The results are shown in table I 0 
for all demographic groups. Eighty-two percent of consumers said they most often 
purchase OTC products from drugstores. 
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Table 10 
WHERE DO CONSUMERS PREFER TO PURCHASE OTCS? 
Category of data %Drugstore (N) %Supermarket (N) Total(N) 
Gender 
Female 84% (92) 11% (12) 110 
Male 78% (42) 15% (8) 54 
Age 
19-24 95% (19)* 5% (1) . 20 
25-34 82% (40) 8%(4) 49 
35-49 80% (39) 14% (7) 49 
50-59 85% (11) 8% (1) 13 
60+ 76% (25)* 21% (7) 33 
Income 
<$10,000 86% (25) 10% (3) 29 
$10-$19,000 69% (20)* 17% (5) 29 
$20-$29' 000 88% (29) 6% (2) 33 
$30-$44,000 79% (33) 17% (7) 42 
$45-$59,000 100% (17)* 17 
>$60,000 69 % (9)* 23% (3)* 13 
Education 
< High School 50% (2)* 50% (2)* 4 
= High School 78% (49) 13% (8) 6) 
Trade School 77% (10) 23% (3)* 13 
4 Year College 88% (44) 8% (4) 50 
> 4 Yr. College 84% (21) 12% (3) 25 
None of the above 88% (7) 8 
Native Language 
English 84% (119) 12% (17) 144 
non-English 78% (14) 17% (3) 20 
* denotes statistical difference for that range compared to other ranges in that category. 
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A few statistical differences were found within categories of data, however, it is 
difficult to explain these findings with such a limited sample. A national Business 
Marketing survey conducted in 1988 revealed in their study sample that consumers 
generally favored buying OTCs in drugstores compared to supermarkets. (11) 
Overall, consumers depend on health care providers to assist them in their decision 
on product selection and moreover, to provide directions for the product. In the Rhode 
Island survey, 34 % of consumer respondents rely on the pharmacist to help them select a 
product while 30% rely on physicians. Figure 2 shows the results for each source. Kline 
& Company reported in their national study a similarity to these findings; 40% of 
respondents rely on physicians while 67% said they asked a pharmacist to recommend 
something. While there was no statistical difference observed between pharmacists and 
physicians as the preferred consultant in the Rhode Island survey, national statistics 
suggest that pharmacists are consulted more often because they are more directly 
accessible to consumers. 
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figure I 
What Was Done About Problems' 
What Was Done '83 vs. '92 
1983 1992 
Used an ll' medication 
33% 
Dtled/went to doctor 
8% Used an ft, medication 
Dlkd/went to doctor 
IS% 
60 
50 
40 
30 
20 
10 
0 
13% 
Used an OTC medication 
IOo/, 
Used a home remedy 
35% 
*Source: Heller Research Group 
33% 
Figure2 
Did not treat 
14% 
Used ""OTC medication 
11% 
'used a home remedy 
26% 
% Of Consumers Who Rely On Different Sources Oflnfluence 
In Selecting OTC Products 
@]! MD ml RPh ~ Family/Friends El Media mil Label 
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An interesting finding in the national data is the fact that more women choose 
drugstores over supermarkets. The Rhode Island study did not reflect a significant 
difference between men and women. Table 10 shows this data. The literature shows that 
'one-stop' shopping is becoming more popular than the usual fashion of shopping at 
specialty stores for different products. The reason for this change is time constraints with 
work schedules, overall convenience, and the use and value for coupons (double coupons) 
in supermarkets compared to drugstores. The Rhode Island survey found that 82% of 
respondents buy their OTC products in drugstore~. Since more women responded to the 
survey it may suggest that more women shop in drugstores and may buy OTC products 
more so than men. A higher statistic for women would be expected and it appears Rhode 
Islanders are still traditional in many of their buying habits. 
Age may be an influential factor since the elderly notably use 11).0re prescription 
drugs, and they traditionally prefer the service and personal relationships established in 
drugstores, specifically independent drugstores. (11) They can conveniently purchase 
OTC medicines in drugstores as well. A study by National Association of Retail Druggists 
and Johnson & Johnson reports 69 percent of consumers over the age of sixty prefer 
drugstores. (11) The Rhode Island found that 76 percent of elderly preferred drugstore 
outlets for their OTC drugs. Table 10 also shows the results for this variable. Overall, the 
Rhode Island survey did not reveal and significant differences between age groups in their 
preference of drugstores to supermarkets. 
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How influential is television advertising? 
With regard to advertising, the Rhode Island ·study determined that 35% of 
consumers are strongly influenced by television advertising. However, when television is 
compared to other venues, advertising in general was only reported to a major factor in 
the choice of OTCs by 7% of respondents. National statistics show that 13 percent of 
consumers believe that advertising is a significant factor in OTC choice. (7) 
What are consumers' perceptions on prescription drugs compared to OTCs? 
In this section of the study consumers were first asked if prescription medicines are 
more effective than OTC products in order to determine their overall attitude about OTC 
drugs. Ninety-one percent of participants indicated that prescription drugs work better. 
Of these 65% concluded that prescription drugs sometimes work better while only 22% 
felt that these products are always superior. Eight percent of consumers felt that 
prescription drugs are never better than OTC products. National statistics show a 
different result, in that only I 0% of respondents felt that prescription rpedicines are likely 
to work better than OTC's. The discrepancy may be due to how the question was asked 
in the Rhode Island survey. In the national survey, consumers had the opportunity to 
compare the usefulness of OTC products to prescription drugs for a variety of conditions, 
and the data support the general satisfaction reported in the wide use of OTC products. In 
the Rhode Island study consumers were given limited choices. 
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Should safe prescription drugs be switched to OTC status? 
Consumers were also asked if safe prescription drugs should be available for OTC 
use. For this question 87% responded favorably to this question. Table 11 displays the 
results for all demographic groups. In general, consumers appear to be in favor of 
continuing the process of switching prescription drugs to OTC status. Some statistical 
differences arise within categories of data, however, it is difficult to apply reasoning which 
would explain such results. To further support this opinion, consumers were asked how 
often they would choose a relatively new switch product over an OTC product which has 
been on the market for a long time. Seventy-five percent would generally prefer a switch 
product (58% sometimes, 17% always). This response confirms the confidence that 
consumers have in the effectiveness of prescription drugs. Heller showed that 50% of 
respondents were more likely to choose switch products. The availability of more OTC 
products from the switch process gives consumers more choice at a lower cost. 
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Table 11 
SHOULD RX DRUGS BE SWITCHED? 
( Income, Education, Language, Age, Gender) 
Category of Data % Good Idea (N) % Somewhat of % Bad Idea (N) 
a Good ldea(N) 
Income 
< $10,000 18% (5) 64% (18) 14% (4) 
$10-$19,000 38% (11) 48% (14) 14% (4) 
$20-$29,000 33% (11) 58% (19) 9%(3) 
$30-$44,000 48%(20) 43% (18) 10% (4) 
$45-$59,000* 18% (3) 59% (10) 24%(4) 
>$60,000 39% (5) 46% (6) 8%(1) 
Education 
< High School 50% (2) 50% (2) 
= High School 27% (17) 56% (35) 15% (9) 
Trade school 54% (7) 38% (5) 8% (1) 
4 Yr. College 42% (21) "50%(25) 8%(4) 
> 4 Yr. College 24% (6) 60% (15) 12% (3) 
None of the above* 13% (1) 50% (4) 38% (3) 
Native Language 
English 32% (46) 55% (78) 13% (19) 
non-English 46% (9) 44% (8) 6% (1) 
Age 
19-24 25% (5) 60% (12) 15% (3) 
25-34 39% (19) 55%(27) 4%(2) 
35-44 29% (14) 58%(28) 13% (6) 
45-59* 23% (3) 38o/o(5) 38% (5) 
60+ 42% (14) 42o/o(l4) l-2% (4) 
Gender 
Males 44% (24) 43% (23) 11% (6) 
Females 28% (31) 58% (63) 13% (14) 
Total 
Respondents 34% (55) 53% (86) 12% (20) 
. 
* denotes statistical difference for specified range compared to other ranges in category 
of data. 
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How well do consumers understand package labels? 
In the Rhode Island study, a special attempt was made to assess consumers' ability 
to understand examples of terminology which appear on package labels. Four terms 
which are used quite frequently in labeling were defined with correct and incorrect simple 
definitions. The consumer was to select the most appropriate definition. Table 12 
displays the terms and the results for correct responses. These terms included: indication, 
contraindication, active ingredient, and hypertension. Since these terms were not 
presented in the context of the package label, the results may be slightly biased. Despite 
this, 68% of the respondents accurately defined 'indication' while 8% defined it 
inaccurately and 24% said they did not know. This pattern was consistent for all four 
terms. The results clearly imply that those respondents reporting labels as understandable 
(92%) overestimate their ability to understand medical terminology. A good portion of 
respondents were not able to define these standard words correctly or even attempt to do 
so. This is a clear signal that there is a need for more improvement in the standard 
terminology approved by the FDA. It does reflect, however, that pharmacists and 
physicians are accurate in their assessment of consumer ~bilities to understand package 
labeling and have some basis, at this point in time, to be hesitant about granting more 
responsibility to the consumer in self-medication. This is discussed later in phase II results . 
It is reassuring that the FDA is extremely conservative in their approval and switching of 
prescription medicines, and they continue to direct a great deal of attention and effort into 
the labeling of these newly available products. 
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Table 12 
Consumer Understandability of Terminology on Labels 
Term __ _ _______ __ __ _ _ __ Correct_____ __ _ ____ Incorrect___ Don't know 
Indication 68% 8% 24% 
Contraindication 48% 18% 34% 
..... 
N 
°' Active Ingredients 67% 34% 7% 
Hypertension 70% 18% 12% 
( 
The research study has raised a number of issues which could have a significant 
impact on the successful use of OTC products in the future. Consumers think they 
understand what is on the label but they frequently don't. Also they often have difficulty 
reading the labels and advanced education experience does not necessarily reduce this 
problem. Clearly these problems need to be addressed quickly to ensure that the more 
powerful switch drugs will be successful as OTC products. 
If manufacturers and regulatory agencies do not find ways to raise the level of 
understanding of information often found on labels, the risk for inappropriate and/or 
unsafe use is likely to increase. Since some switch products are intended to "cure" certain 
conditions, patients must clearly understand how, when, and how long to use the products 
to effect the desired result.(13) With regard to readability oflabels, attention must also be 
given to designing labels which contain appropriate information in a clearly readable type 
and style to allow the safe use of the products.(9) Perhaps packaging in larger container 
(e.g. blistapak, larger volume), will improve the readability of the label since larger type 
and easier to read formats could be used. At some point a balance needs to be found 
between the amount of required information and the ease of reading and understanding of 
material on the label. If regulatory agencies are reluctant to reduce the amount of required 
labeling for safe use of these products, a method should be devised to insure that 
consumers are able to receive additional explanatfons and cautions from another venues 
(e.g. videos or computers at the counter for first time users, and accompanying pamphlet, 
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required counseling by a health professional etc .. ) Perhaps manufacturers could educate 
the population using mass media. 
Do consumers find OTC package labels readable? 
Consumers were also given the opportunity to assess the readability and 
understandability of OTC package labels. Tables 13 presents these results. From the 
overall sample, 98% of consumers said that they read OTC package labels. Only 2% said 
they did not read labels. The survey went a step further with regard to.label readability 
based upon label appearance and understandability of the information provided. Thirty -
two percent of the sample reported that the label was not difficult to read and 92% said 
the label was understandable. This compares favorably to the Princeton national study 
which found 90% of respondents who read OTC labels said they understood the labels. 
r 
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The Heller study reported 90% of the respondents acknowledged the importance of 
reading labels and did so before taking an OTC medication. The Rhode Island study was 
unique in that both label readability and understandability was addressed 
This study clearly showed that most people read OTC labels. (Table 12) When 
asked about the ease of reading the label based on the appearance, i.e., word selection 
type style and size, placement, bullets, etc., 32% consumer responded that labels were 
difficult to read, while 65% said OTC labels were difficult to read. Thirty percent of 
women reported labels were readable, while 70% thought labels were difficult to read. 
Men on the other hand reported difficulty in reading labels (60%) and for labels being 
readable (39%). These differences were not statistically significant. 
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Sixty-seven percent of respondents between the ages of25 - 50 reported difficulty 
in reading labels compared to 80% over the age of sixty. This increase with age is not 
unexpected since the elderly often have vision impairments. Many older Americans neglect 
their vision or wear improper corrections lenses. Also degenerative diseases often 
contribute to reduced vision. Educational levels had some effect on ease of reading the 
label. In those who had a trade school education, 90% reported difficulty in label reading. 
Generally 50% of the respondents with a high school education reported difficulty in label 
reading compared to 60% of those with a baccalaureate education. Among advanced 
degree respondents about 55% reported some difficulty in reading labels. 
These data indicate that many people consider labels difficult to read. The reasons 
why are not specified but may include too much information in a limited space, small type, 
color, and label format. Clearly one would also expect that reading in general becomes 
more difficult as we age. 
One would not expect to find a difference in readability based on gender, although 
national studies have shown that women read labels more then men, and as a result of 
being the primary care giver in the home, are more conscientious about reading the label 
thoroughly. Surprisingly, more education did not result in less difficulty in reading and 
understanding labels. It could be that only a certain level of education is necessary for a 
person to interpret medical terms. 
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Table 12 
LABEL READABILITY AND UNDERSTANDABILITY 
Read Labels Readable Understand 
Category of Data % Yes (N) % Yes(N) %Yes (N) 
Gender 
Males 89% (48) 31%(17) 89% (48) 
Females 95% (105) 31% (34) 93% (101) 
Native Language 
English 96% (138) 35% (50) 94% (133) 
non-English 75% (15) 5% (1) 80% (16) 
Education 
<High School 75% (3) 100% (4) 
=High School 91% (58) 31% (19) 90% (56) 
Trade School 92% (12) 15% (2) 92% (12) 
4 Yr. College 98% (49) 37% (18) 95% (47) 
> 4 Yr. College 92% (23) 40% (10) 79% (23) 
( None of the above 88% (7) 25% (2) 75% (6) 
Income 
<$10,000 89% (26) 25% (7) 93% (26) 
$10-$19,000 90% (26) 28% (8) 89% (26) 
$20-$29,000 96% (43) 34% (11) 88% (28) 
$30-$44,000 95% (40) 31% (13) 93% (39) 
$45-$59,000 100% (17) 41 o/o' (7) 100% (17) 
>$60,000 84% (11) 33% (4) 91% (12) 
Age 
19-24 95% (19) 50% (10)* 95% (19) 
25-34 94% (46) 29% (14) 89% (43) 
35-44 94% (46) 33% (16) 94% (45) 
45-59 92% (12) 38% (5) 92% (12) 
60+ 91% (30) 18% (6)* 91% (30) 
Total 
Respondents 92% (153) 32% (51) 92 (151) 
* denotes statistical difference 
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r Phase II: Health Professional Survey 
In phase II of this study physicians and pharmacists were asked to provide 
information about the following areas: their prescribing habits, views on the Rx to OTC 
switch, patient characteristics which may effect the selection and safe use of OTC 
products, and finally package labeling and its effect on OTC use. 
Do Health Professionals approve of the trend of patient self-medication? 
With the shift in health care towards placing more responsibility on consumers for 
their own self-care, it is important to research whether health care professionals are ready 
to adjust some of their practices and attitudes regarding patient self-medication. When 
asked about their approval of the trend of patient self-medication 50 percent of physicians 
and 74 percent of pharmacists responded favorably. Thirty-five percent of physicians and 
23 percent of pharmacists responded unfavorably. The results for physicians and 
pharmacists regarding their approval of patient self-medication are statistically different. 
The difference may be accounted for by the roles each professional plays with respect to 
medication. Pharmacists are more aware of the extent and types of information 
consumers obtain and may therefore have more confidence in their ability to self-medicate 
in a responsible manner.(Figure 3) 
Do Health Professionals approve of switching prescription drugs to OTC status? 
The Rhode Island study asked both health care professional populations about 
their perceptions of the trend of switching prescription medicines to OTC status. Figure 3 
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shows that from the physician group, 26 percent approved of the switching, 31 percent 
were not sure, compared to 39 percent that did not. Among pharmacists, 39 percent 
approved of the switch trend, 26 percent were not sure, while 34 percent did not approve. 
To further evaluate this issue, both groups were asked whether drugs with safe and 
established histories should be switched to OTC status. It was interesting to see that 35 
percent of physicians and 67 percent of pharmacists felt all, or some drugs should be 
switched. From this data, it appears that health care professionals are concerned about 
allowing consumers to self-medicate, however, they are in favor of increasing the selection 
of products by switching more effective prescription medicines to assist them in their 
practice of self-medication. It is difficult to understand the reluctance of these groups to 
be more supportive of switching prescription products to OTC status. (Figure 3) 
How often do Health Professionals recommend OTC products? 
Eighty-eight percent of both physicians and pharmacists recommend OTC 
products to consumers with confidence. Therefore, they recognize the usefulness of these 
products in part of the health care of their patients. (Figure 3) 
These two groups were then asked about their habits for recommending switch 
products. (Table 13) Eighty-nine percent of physicians and 96 percent of pharmacists 
routinely recommend switch products. Only 26 percent of physicians and 40 percent of 
pharmacists approved of switching prescription drugs for the purpose of enhancing self-
medication .. These data would seem to contradict their views on limiting the switch of 
prescriptions to OTC status for the purpose of enhancing self-medication. In the 
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recommendation process for a switch product, both groups provide a product name and 
explicit directions for use. Perhaps they feel this additional guidance is needed to ensure 
appropriate use of switch products. 
Other factors that were considered as reasons why doctors and pharmacist 
displayed caution about switching and patient self-medicating may be related to their 
current knowledge on what OTCs are available, and what source of information 
consumers rely on for their selection of OTC products. For these reasons, pharmacists 
and physicians were asked about what source they rely on to keep abreast on OTC drug 
products and corresponding information. It was found that most physicians(52%) and 
pharmacists(67%) depend on professional journals to update them about new products in 
the OTC market. Other sources include detail men/women, seminars, direct mailings, 
television, and package labels. The Kline study reported 41 percent of physicians relied 
on detail persons and only 14 percent used journal advertising as a vehicle.(5,7) 
.Additionally, they were asked to speculate about the type of advertising which their 
patients rely upon for OTC product selection. Since advertising of OTCs on television 
was expected to rank higher than other sources (5,7), a question about the informational 
content of the advertisements was included. Both physicians and pharmacis!s agreed that 
television advertisements do not convey important information which may help consumer 
in OTC product selection or proper use of it. 
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Are Pharmacists important sources of information? 
Both physicians and pharmacists recognize the importance of a health care 
professional being accessible to consumers for OTC product information. Seventy-five 
percent of physicians and 97 percent of pharmacists responded that the information 
provided by pharmacists is important to assist consumer~ in using OTC products safely. 
Fifteen percent of physicians and two percent of pharmacists say this information is not at 
all necessary to ensure the safe use of OTC products. 
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Figure3 
% Of Physicians and Pharmacists Who Approve Of 
Self-medication, Trend Of Switching Rx Drugs For Improved Self-medication, 
Recommend OTC Drugs, and Switching Safe Drugs 
Doctors RPhs I 11 self-med II switch trend Ill re~ OTC ~ switch safe drugs I 
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Table 13 
HEALTH PROFESSIONAL OTC RECOMMENDING PRACTICES 
Category of Data 
Recommend OTCs 
Recommend switch OTCs 
Prescribed/dispensed now OTCs 
How often recommend switches: 
Under 10% 
10-24% 
25-59% 
Method of recommending: 
Name and directions 
AskMD/RPh 
Name and label for info. 
%Physicians(N) 
90% (139) 
89% (132) 
87% (134). 
48% (69) 
28% (40) 
8% (11) 
63% (95) 
6% (9) 
24% (36) 
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%Pharmacists (N) 
88% (157) 
96% (165) 
90% (161) 
37% (62) 
30% (50) 
17% (28) 
7-7% (129) 
4% (6) 
16% (26) 
( 
What patient characteristics influence the selection of OTC products? 
The patient characteristics that physicians and pharmacists believe influence the use 
of OTCs are described. Figure 4 shows the results for each characteristic categorized by 
physician and pharmacist groups. Most professionals selected education, age, and 
language skills as the characteristics necessary to effect the safe and proper use of OT Cs. 
For education, 91 % of physicians and 90% of pharmacists believe this is the most 
important characteristic for the appropriate use of OTC medicines. A patient must be 
educated enough to understand the information provided. A limitation to the study was 
that it did not ask physicians and pharmacists how and to what extent certain 
characteristics affected the proper use of OTC products. Eighty-eight percent of 
physicians and 89% of pharmacists feel that age contributes to patient decisions in using 
OTC products. Twenty-six percent of physicians and 23% of pharmacists believe that 
language skills are an important parameter. The income and gender factors do not in their 
opinion have significant impact. 
Other influential factors identified were package labels (10%), friends and family 
(10%). Nationally pharmacist or physician consultation were primary factor-s used to 
select particular OTC products.(5, 7) In the Rhode Island study, consumers were asked to 
select the most important factor which influenced their s~lection whereas the Kline study 
allowed respondents to select all appropriate factors. While the results are not directly 
comparable, they do show that consumers rely primarily on professional information in 
their choice of OTC products. 
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Figure4 
% Of Physicians and Pharmacists Who Believe Certain 
Patient Characteristics Affect The Proper Use Of OTCS 
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Are labeling changes necessary for the success of OTC products? 
( 
Physicians and pharmacists were asked about completeness of label information on 
prescription and OTC products. In the comparison of the OTC package label to a label 
and counseling associated with a prescription product, (counseling includes verbal or 
written information on the purpose of use, direction, side effects, and warnings for the 
drug prescribed and dispensed), 34 percent of physicians and 45 percent of pharmacists 
believed that an OTC label was less detailed than the information provided with a 
prescription product. Among the remaining respondents, 22 percent of physicians and 34 
. 
percent of pharmacists believed the OTC label was more detailed, 11 percent of physicians 
and 12 percent of pharmacists considered both types of information equal, 6 percent of 
physicians and 12 percent of pharmacists regarded neither sources of information was 
sufficiently detailed. Table 14 shows these results. 
( 
A rather alarming finding was that 27 percent of physicians reported that they did 
not know which was more detailed and 29 percent did not know which was more 
understandable. Since physicians are involved in recommending OTC products for 
patients, they should be aware of what information is presented on the labels. 
It was expected that both physicians and pharmacists would recogni2;e that more 
detailed labeling is required on an OTC product since a patient is expected to use it 
without the supervision or intervention of a health professional. Clearly physicians do not 
show a distinct awareness of the amount of information available with either OTC or 
prescription products. Pharmacists who routinely fill prescriptions are aware of the 
volume of information associated with dispensing a prescription product compared to an 
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OTC label. Perhaps pharmacists in their responses are including OBRA regulations as 
part of the counseling and are therefore associating more detailed information available 
with prescription products rather than with OTC products. 
With respect to the understandability of OTC label information compared to 
prescription information, a different pattern in responses is observed. Forty-five percent 
of physicians and 55 percent of pharmacists said OTC labels are less understandable than 
dispensed and counseled prescriptions, while 13 percent of physicians and 20 percent of 
pharmacists said OTC labels are more understandable. As far as the labels being equal in 
this aspect, 21 percent of physicians and 16 percent of pharmacists reported this. A small 
group of them believe neither types of information are understandable. Once again, an 
astounding 29 percent of physicians do not know. 
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Table 14 · 
MD AND RPH VIEWS ON LABEL INFORMATION 
Category of Data % Physicians (N) %Pharmacists(N) 
Label Detail 
Dosage 79% (115) 86% (152) 
Directions 86% (124) 89% (158) 
Indications 48% (70) 58% (102) 
Ingredients 56% (81) 65% (115) 
Purpose of Ingredients 10% (14) 6% (11) 
Side effects 31% (45) 33% (58) 
Warnings 49% (71) 63% (111)* 
Contraindications 37% (54) 40% (70) 
( Label Understandability 
Dosage 76% (108) 75% (131) 
Directions 80% (113) 77% (134) 
Indications 38% (54) 41% (72) 
Ingredients 19% (27) 27% (47) 
Purpose of Ingredients 4% (6) 7% (12) 
Side effects 22% (31) 26% (46) 
Warnings 28% (40) 41% (71)* 
Contraindications 25% (35) 22% (38) 
- The percentages listed here represent favorable responses. 
* Represents statistical difference based upon the Chi-square test. 
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Summary of Findings 
Phase I- Consumers 
• Approximately 97 percent use Over-the-Counter Medicines (OTCs). Of these, 31 
percent use them always, 57 percent use them sometimes, and nine percent use them 
rarely. Three percent of people say they never use OTCs. Study population contained 
drug-store patrons which may have influenced results. 
• 97 percent of consumers read OTC package labels. Sixty-five percent say they read 
OTC labels always while 4 percent read them rarely. Only 2 percent of the 
respondents say they never read OTC labels. 
• 65 percent of consumers feel OTC package labels are readable and 92 percent of them 
feel the labels are understandable. Thirty-one percent of consumers feel labels are not 
readable and only 5 percent feel labels are no(understandable. 
• 81 percent of consumers said they prefer to purchase OTC medicines in drugstores 
while 12 percent resort to supermarkets. (Study population contained drug-store 
patrons) 
• 34 percent of consumers consult with pharmacists when choosing an appropriate OTC 
product while 29 percent contact their doctors. Ten percent of consumers refer to 
family or friends for help. 
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• 10 responded that using the package label was the primary factor in selecting a 
product and an additional 10 percent are influenced by price or a discount coupon for 
selecting the product. 
• Of the respondents, 87 percent were in favor of switching prescription medicines with 
safe histories for OTC use. 
143 
( 
( 
Phase II 
Physicians and pharmacists 
• The general consensus among physicians and pharmacists for the trend towards self-
medication is favorable. Fifty percent of physicians approved of this trend while 72 
percent of pharmacists approved of this trend. 
• Both groups of professionals agree on certain patient characteristics which may affect 
the safe and proper use of OTC medicines. In rank order, these include education, age, 
language skills, income, and gender. 
• 70 percent of physicians and 95 percent of pharmacists felt some drugs with safe and 
established histories should be switched to OTC medicines for the improvement of 
patient self-medication. 
• With regard to pharmacists being helpful sources of OTC drug information, 70 percent 
of physicians said they were, 7 percent said not much, 2 percent were not sure and 15 
percent responded as not at all. With pharmacists on the other hand, 96 percent 
responded that they were important for OTC information, 2 percent were not sure, 
and 2 percent said not at all. 
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• 50 percent of doctors said they frequently recommend OTC products to their patients, 
forty percent said sometimes, 4 percent rarely and 3 percent do not recommend OTCs. 
The manner in which they recommend OTCs may influence this finding. Generally, the 
physician provides a product name and explicit directions for use. 
• 69 percent of pharmacists frequently recommend OTCs to patients, 19 percent 
sometimes do, 2 percent rarely recommend and three percent do not recommend. The 
method of recommending for pharmacists is consistent to that of physicians . . 
• With regard to the "detail" of information provided on package labels, doctors 
responded favorably to the dosage, directions, and ingredient sections on the label. 
Pharmacists responded favorably to these same areas and additionally to the warning 
sections of the labels as being sufficiently detailed: 
• With regard to the "understandablility" of label information, both doctors and 
pharmacists responded favorably to the dosage and directions sections only. The 
remaining label information sections not considered understandable were the 
indications, ingredients, purpose of ingredients, side effects, warnings, and 
contraindications. 
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IV. Summary and Future Work 
Both consumer and professional groups are supportive of self-medication trends, 
and they have confidence in switch products. Physicians and pharmacists however are 
reluctant to provide wide ranging choices of switch products to consumers without 
supervision. This is evident in their responses about recommending switch products. In 
the majority of respondents when switch and OTC products are recommended, consumers 
are provided with a specific tradename product along with explicit directions for use. 
When queried about patient characteristics necessary for appropriate use of these 
products, both professional groups identified age, education and language skills as pre-
requisite to successful use of these products. Perhaps physicians and pharmacist have low 
confidence in a patient's ability to make crucial interpretations of product information. On 
the other hand, they may also prefer to maintain their professional role in evaluating and 
recommending products as consumers move into the arena of self-care. 
Currently, the Food and Drug Administration is conducting a study regarding label 
terminology and consumer comprehensibility of it. It is well established that there is a 
need for uniformity of package labeling but more importantly, the terminology used in the 
labeling must be standardized for a certain level of comprehension. More research must 
be carried out to determine what qualities consumers should have to assist them or 
enhance their ability to read and undertstand labels. Knowing these qualities will facilitate 
the FDA in the development of appropriate label information. 
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APPENDIX A 
Surveys 
For Office Use Only 
STR 
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Dear Consumer: 
A ve.cy important issue for health care today is the switching of prescription-only 
medicines to over-the-counter medicines. This trend continues to be favored by regulators, 
manufacturers, health care professionals, and consumers. AJ. the same time, a concern has been 
raised about whether pack:a.ge labeling provided by manufacturers is sufficient and understandable.. 
My research project focuses on this concern. Specificlly, the research is assessing whether 
current package information is indeed sufficient to ensure safe and proper use of over-the- · · 
counter products by consumers. 
I would greatly appreciate your taking five minutes of your time to answer the questions in 
this survey. When you have completed the survey, please fold and place it in the box on the 
check out counter or give it to the pharmacist on duty. Thank you. 
Nancy M Hewitt, R.Ph. 
Fogarty Hall 
Department of Pharmaceutics 
University of Rhode Island 
~gston, RI 02881 
Thank you for your help. 
: _ _ . _ '_ . _ _ ___ . ·:· , ··. ___ _ ·;_· · ·;~~Y ... ~:,.::~:r;:_:~~;.·;:··:::.f~x~~;~'<·~~ 
i BE ASS·URE·D :fHA.f . .\Li'RE:s;ONSES wi:r.L BE KEPT STRI~; CONF·tni'N~ '.':;,;.;&;; 
. . . . .. -~ 
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CONSUMER QUESTIONNAIRE 
In each section, please choose one response to the following questions. Place a mark in the box next to the 
most a ro riate choice. 
~~~~i4'~'1 A .. Over-the-Counter Medicines: -:: How.you '.choose a ·product·/st;fpir.fi~f4f. 
1.) How often do you use over the counter medicines? 
0 always 
0 sometimes 
0 rarely 
0 never 
[If never, please skip to section 8, question #5 ) 
2.) Where do you purchase over-the-counter medicines most often? 
0 drugstore 
0 supermarket 
0 department store 
0 convenience store 
0 health maintenan~ oiganiz.atlons (HMOs) 
0 other (please specify) _______ _ 
3.) Who or what is the most Influential source In your decision to use a particular over-the-counter product? 
0 doctor 
0 pharmacist 
0 friends/relatives 
0 television/ radio/ magazine advertisements 
0 package label 
0 other (please specify) _______ _ 
4.) How much do television advertisements for over-the-counter medicines influence you in choosing a product? 
0 very much 0 none 
0 somewhat 0 do not watch television 
0 very little 
t~&:k~M,s~J~~adin9Ae..acka9~~EabetS;#.f1Qver~tti~.;,co.anterMeaiC.ifie5?~&_.._.,,. 
5.) Do you read package labels on any over the counter medicines? (either in stores or after you purchase them) 
0 always 
0 sometimes 
[It never, please skip to question #12 ] 
0 rarely 
0 never 
6.)Please consider the overall appearance of a tyical over-the-counter package. 
a.) Is the over-the-counter package label difficult to read? 
0 very difficult 
0 somewhat difficult 
0 not difficult at all 
0 not sure 
b.) Is the over-the-counter package label difficult to understand? 
0 very understandable 
0 sor.iewhat understandable 
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0 not sure 
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7.) The tenn indication appears on all over-the-counter product labels. What does this term mean to you? 
::J a cure for a condilion 
~ a specific use or a symptom(s) the product will help minimize or reduce 
0 the prevention of a symptom 
0 do not know 
3.) The tenn contraindication appears on all over-the-counter product labels. What does this tenn mean to you? 
:J the side effects of the medicine 
0 conditions and/or medicines with which the product should not be used together 
0 the directions of how to take the medicine 
0 do not know 
2 
~-) In the warning section of some over-the-counter product labels, the word hvpertenslon Is mentioned. The label says , 
i:eople who have hypertension should not use the product. What do~ _this word mean to you? · · 
0 a condition of too much tension or stress 
0 a condition of low blood pressure 
0 a condition of high blood pressure 
0 do not know 
10.) The active and inactive ingredients are listed on package labels, which type of ingredient will help reduce symptoms 
~ active _ingredients 
~ inactive ingredients 
0 both kinds of ingredients 
0 neither kind of ingredient 
0 do not know 
11.) Should manufacturers place package inserts( a piece of paper containing drug infonnation ) inside packages of 
over-the-counter medicines? 
0 yes; in English 0 no it is not necessary 
0 yes; in two languages 0 do not use over-the-counter medicines 
12.) The Government is considering making several prescription-only medicines available as over-the-counter medicines. 
This means you will no longer need a doctor's order to purchse them. Is the idea of switching these medicines: 
lJ a good idea (more medicines available wilhout a prescription the better) 
0 somewhat of a good idea (only some medicines should be) 
] a bad idea (keep lhe medicines by doctor·s order only) 
J I do not use prescription medicines 
15 l 
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13.) Within the large selection of over-the~unter medicines.there are several medicines which used to be available by 
prescription-only. Considering all these products you have to choose from.how often would you choose the one which 
used to be available as prescription-only? 
0 always the product which used to be a prescription 
0 sometimes the product which used to be a prescription 
0 rarely the product which use to be a prescription 
0 never the product which used to be a prescription 
0 the product which has always been an over the counter medicine 
0 none of the above 
14.)Do you believe that presafpUon medicine works better than over-the-<:aunter medicine? 
0 yes, always 
0 yes, sometimes 
0 yes, rarely 
0 no 
0 I do not use medicine 
l~~mtBn*P.ER's:oNAtliNEORMATiO .. . .'::':':\l ... ·' ,-.. ···---~·· ···" · ···· · .-. ...... . · .. l!f . . 
15.) In each of the following categories, please mark one selection: 
A.Age: B. Last school completed C. Individual Annual Income 
0 under 18 
0 19-24 
0 25-34 
0 35-49 
0 50·59 
0 60+ 
0. Native Language 
0 English 
0 Spanish 
0 Portugese 
0 Other 
0 Less than High School 0 
0 High School or Equiv. 0 
0 Trade School 0 
0 4 Year College 0 
0 More than 4 Years College 0 
0 None of the above 0 
E. Sel_C 
0 Female 
0 Male 
THANK YOU FOR YOUR TIME AND EFFORT 
Nancy M. Hewitt, R.Ph. 
Department of Pharmaceutics 
Univeristy of Rhode Island 
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Dear Physician: 
A vccy important issue for health care today is the switching of prescription-only 
medicines to over-the~unter medicines. This trend continues to be favored by regulators, 
manufacturers, health care professionals, and consumers. Af the same time, a concern has been 
raised about whether package labeling provided by manufacturers is sufficiently comprehenstl>le. 
My research project focuses on this concern. Specifically, the research is assessing .. 
whether current package information is indeed sufficient to ensure safe and proper use of over-
the-<ounter products by consumers. 
I would greatly appreciate your talcing five minutes of your time to answer the questions in 
this survey. I have enclosed a pre-addressed and stamped envelope for your convenience. Please 
return this form to: 
Nancy M Hewitt, R.Ph. 
Fogarty Hall 
Department of Pharmaceutics 
University of Rhode Island 
Kingston, Rl 02881 
Please postmark no later than March 10, 1994 
Thank you for your help. 
OE ASSURED TIIAT ALL RESPONSES WILL OE KEPT STRICTLY COt'.rIDENTfAL 
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PHYSICIAN QUESTIONNAIRE 
Please respond to the following questions based upon your scope or practice by placing a check 
mali( next to the most appropriate choice. 
1.) As a health care professional, do you approve of the movement toward more 'patient self-medication' 
with over-the-counter medicines (OTC)? 
0 very much so 
0 somewhat 
0 not sure 
0 no 
0 not familiar with issue 
2.) Over-the-counter medicines are used to treat minor ailments. Do you believe that any of the 
following patient characteristics affect the safe and proper use of OTC medicines? 
[Please check all that apply] 
0 age 0 gender 
0 education 0 language skills 
0 level of income 0 other.-----------
3.) Currently, there is a trend of switching presaiption-only medicine to over-the-counter medicine status. 
Do you think this trend improves patient's self-medicating habits? 
0 very much 
0 somewhat 
0 not much 
0 notatall 
0 not familiar with trend 
4). Some prescription-only products have established histories as being safe and effective. Should such 
products be made accessible to patients for self-medication without a prescription? 
0 all such products 
0 some of these products 
0 very few products 
0 no such products 
0 do not know 
5.) Have you ever 'dispensed' a product which has since been switched to OTC status or is now 
available as nonprescription strength? 
0 yes 
0 no 
0 not sure 
0 not applicable to my scope or practice 
6 .) In the last six months. have you recommended any OTC products to patients? 
0 frequently 
0 sometimes 
Q rarely 
0 no 
0 not applicable lo my scope or practice 
[IF NO OR NOT APPLICABLE.PLEASE SKIP TO QUESTION 1:10] 
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7.) Have you 'recommended' any OTC products which were formerly available as prescription-only? 
0 yes 
0 no 
0 not sure 
8.) Of the OTC products you have recommended, what percentage would represent switched products 
(formerly a prescription-only product)? 
0 under 10 percent 0 50 - 7 4 percent 
0 1 o - 24 percent 0 75 - 99 percent 
0 25 - 49 percent 0 100 percent 
0 not sure 
9.)ln what manner do you most often recommend an OTC product to a patient 
(Please check only one] 
0 suggest a product name and provide explicit directions 
0 suggest asking pharmacist for product and directions 
0 suggest a product name but allow patient to rely on package for directions 
0 do not recommend OTC medicines 
G not applicable to my scope of practice 
10.) Manufacturer labeling of OTC packages provides descriptive information which is designed to 
promote the safe and responsible use of the product. 
a.) In which of the areas listed below, is the provided information sufficiently detailed 
for the patients? 
0 Dosage 
0 Directions for use 
0 Indications for use 
0 Ingredients (inactive and active) 
[Please check all that apply) 
0 Purpose of each ingredient 
0 Side effects 
0 Warnings 
0 Contraindications 
0 Other. ___________ _ 
b.) In which of the areas listed below is the provided information sufficiently understandable 
for the patients? [Please check all that apply] 
0 Dosage 0 Purpose or each ingredient 
0 Directions for use 0 Side effects 
0 Indications for use 0 Warnings 
0 Ingredients (inactive and active) 0 Contraindications 
0 Other. 
2 
155 
( 
( 
11 .) Pharmacists label prescription bottles and provide verbal counseling about the prescription 
medication. Compared to the information the patient receives from the pharmacist and the Rx bottle: 
a.)ls the information provided on an OTC package label: 
0 less detailed than a prescription product 
0 more detailed than a prescription product 
0 both forms of information are equal 
0 neither information is sufficient 
0 do not know 
b.)ls the information provided on an OTC package label: 
0 less understandable than a prescription product 
0 more understandable than a prescription product 
0 both forms of information are equal 
0 neither information is sufficienUy comprehensible 
0 do not know 
12.) Is the information provided by pharmacists about OTC products important to ensure the safe and 
proper use of OTC products by patients? 
0 very much 
0 somewhat 
0 notmuch 
0 notatall 
0 do not know 
13.) Advertisements for over-the-counter medicines appear in most forms of media. On which source do 
you rely most heavily to keep you updated or informed about new products available in the OTC 
mar1tet?(please check only one source] 
0 newspaper 0 direct mailings (brochures) from manufacturers 
0 professional journals 0 p_ackage labels 
0 nonprofessional journals 0 · professional seminars 
0 television 0 other 
14.) Which form of advertising for OTC products do you believe has the most influence on patients in 
choosing an OTC product? 
0 newspaper 0 instore displays 
0 television 0 friends/relatives 
0 journals (all nonprofessional) 0 other. 
0 package labels 
15.) Do you believe that television advertisements for OTC products provide sufficient information in any of 
the following areas?[Please check all that apply) 
0 indications for use 0 warnings 
0 directions for use 0 contraindications 
0 side errects 0 other: 
J 
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l'or Office Use Only 
SVR 
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NFO 
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COT 
Dear Pharmacist: 
A very important issue for health care today is the switching of prescription-only 
medicines to over-the-<:ounter medicines. llis trend continues to be favored by regulators, 
manufacturers, health care professionals. and consumers. A1 the same time, a_ concern has been 
raised about whether paclcage labeling provided by manufacturers is sufficiently comprchenst'ble. 
My research project focuses on this concern. Specifically, the research is assessing 
whether current paclcage infonnation is indeed sufficient to ensure safe and proper use of QYCC-
the-<:<>unter products by consumers. · · 
I would greatly appreciate your talcing five minutes of your time to answer the questions in 
this survey. I have enclosed a pre-addressed and stamped envelope for your convenience. Please 
return this form to: 
Nancy M Hewitt, R.Ph. 
Fogarty Hall 
Department of Pharmaceutics 
University of Rhode Island 
Kingston, RI 02881 
Please postmark no later than March 10, 1994 
Thank you for your help. 
IlE ASSURED THAT ALL RESPONSES WILL IlE KEPT STRICTLY CONFIDENTIAL 
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Appendix B 
CONCLUSIONS AND FUTURE WORK 
This dissertation has presented important policies and issues stemming from the 
switching of prescription-only medicines to Over-the Counter (OTC) status. 
1. The FDA and drug manufacturers have expended considerable effort in the 
development of regulations, reveiw processes, and labeling to provide consumers with 
non-prescription products which are safe and effective when used according to 
directions. 
2. Switching products from prescription to OTC status has provided consumers 
and health professionals with products in which they have confidence. 
3. Consumers rely primarily on physician and pharmacist recommendations in 
their choice of OTC products, while only about 10% report that television has a 
significant impact on their selection. Physicians and pharmacists believe however that 
consumers are significantly influenced by television advertising in product selection. 
4. Many consumers routinely read OTC product labels at the time of purchase 
and first use. Although labels are designed to provide information in easy to read 
formats and understandable terminology, it is clear from this study that consumers have 
difficulty reading and interpreting them. Physicians and pharmacists agree that some 
158 
portions of the label are difficult for consumers to understand. Given these results, it is 
crucial that regulatory agencies and drug manufacturers develop ways to address these 
problems to insure safe and effective use. The appearance of more potent prescription 
products in the OTC market compounds the problem and increases the risk of adverse 
effects and misuse. 
5. While physicians and pharmacist are supportive of the self-care trend, they are 
not wholly convinced that consumers are capable of making all decisions related to self 
medication. Evidence is given to show that when they recommend an OTC or newly 
switched product, they provide the consumer with a specific product name and give 
particular instructions for use. 
6. Future Work: Although this study brought to light some important issues 
related to the continued success of OTC products, it did not provide sufficient 
information about the following: 
a. The degree to which physicians and pharmacists feel particular patient 
characteristics affect their ability to use OTC products successfully. A study should be 
designed to identify specific age, education and language levels which are thought to be 
required to insure appropriate use of these products. The extent to which these 
perceptions agree with consumer views should be studied to identify issues which may 
hinder use of OTC products. 
159 
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b. Labeling: This study identified that labels are a particular problem for 
both consumers and heath professionals in terms of readability and comprehension. A 
study needs to be initiated to find more appropriate ways to improve the ease of reading 
labels and understanding of label contents. 
c. The extent to which health care providers need to be involved in 
successful use of OTC products. It is evident from this study that consumers are 
enthusiastic about the use of OTC switch products, but physicians and pharmacists are 
unwilling to give their whole hearted support to this practice. A study could be designed 
to investigate why health professionals feel this way, and to see if health care 
professionals can use their professional knowledge in more innovatives ways. Also other 
primary health care providers need to be assessed for their impact and perceptions on 
OTC drug use. 
d. The extent to which economics impact the use of OTC products, and 
the effect this has on future use of those products. Clearly OTC drugs are becoming a 
significant part of patient care. The trade off between economic benefit to 
appropriateness of use should be studied. 
160 
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